← Back to search
2m5n

Atomic-resolution structure of a cross-beta protofilament

Method: SOLID-STATE NMR Dmax: 49.5 Å Quality: EXCELLENT
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Transthyretin

OrganismNot specified

UniProt P02766

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Protein homooligomer Homooligomer Protein × 16 PDB declaration: hexadecameric（16） Consistent with protein copy count Chain A； UniProt 125–135 Chain B； UniProt 125–135 Chain C； UniProt 125–135 Chain D； UniProt 125–135 Chain E； UniProt 125–135 Chain F； UniProt 125–135 Chain G； UniProt 125–135 Chain H； UniProt 125–135 Chain I； UniProt 125–135 Chain J； UniProt 125–135 Chain K； UniProt 125–135 Chain L； UniProt 125–135 Chain M； UniProt 125–135 Chain N； UniProt 125–135 Chain O； UniProt 125–135 Chain P； UniProt 125–135 Fragment：UNP residues 125-135 No other associated polymer SOLID-STATE NMR NMR measurement conditions：pH 2；Pressure ambient NMR sample composition：15 mg/mL [U-100% 13C; U-100% 15N] TTR(105-115), 10% acetonitrile/water solution | 10% acetonitrile/water solution Resolution not provided

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 2M5N Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1BM7 HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID) Deposited 1998-07-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.4；pH 7.4
Resolution 2.00 Å R-free 0.251
1BMZ HUMAN TRANSTHYRETIN (PREALBUMIN) Deposited 1998-07-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–143（114 aa）
Chain B 30–143（114 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.4；pH 7.4
Resolution 2.00 Å R-free 0.244
1BMZ HUMAN TRANSTHYRETIN (PREALBUMIN) Deposited 1998-07-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–143（114 aa）
Chain B 30–143（114 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.4；pH 7.4
Resolution 2.00 Å R-free 0.244
1BZ8 TRANSTHYRETIN (DEL VAL122) Deposited 1998-11-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：TRINUCLEOTIDE DELETION VARIANT DELVAL122 Mutation：TRINUCLEOTIDE DELETION VARIANT DELVAL122 No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；pH 6.50
Resolution 2.00 Å R-free 0.277
1BZD TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1998-10-28 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：G6S Mutation：G6S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；PURIFIED PROTEIN (20MG/ML IN 25MM MONOBASIC SODIUM PHOSPHATE BUFFER, 0.15M NACL) WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
Resolution 1.90 Å R-free 0.265
1BZE TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1998-10-28 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：M119T Mutation：M119T No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；PURIFIED PROTEIN (10MG/ML IN TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
Resolution 1.80 Å R-free 0.273
1DVQ CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN Deposited 2000-01-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.223
1DVS CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL Deposited 2000-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded STL RESVERATROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.00 Å R-free 0.227
1DVT CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFEN Deposited 2000-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded FLP FLURBIPROFEN × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.220
1DVU CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACID Deposited 2000-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded DBF DIBENZOFURAN-4,6-DICARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.220
1DVX CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAC Deposited 2000-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride potassium phosphate ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å R-free 0.215
1DVY CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID Deposited 2000-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded BPD N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.203
1DVZ CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID Deposited 2000-01-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–124（124 aa）
Chain B 1–124（124 aa）
Not recorded OFL O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；potassium chloride, potassium phosphate, ammonium sulfate, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.200
1E3F Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-06-14 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–145（125 aa）
Chain B 21–145（125 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；pH 5.50
Resolution 1.90 Å R-free 0.252
1E4H Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-07-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded GOL GLYCEROL × 4 PBR PENTABROMOPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；pH 5.50
Resolution 1.80 Å R-free 0.235
1E5A Structure of human transthyretin complexed with bromophenols: a new mode of binding Deposited 2000-07-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded TBP 2,4,6-TRIBROMOPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；pH 5.50
Resolution 1.80 Å R-free 0.262
1ETA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain 1 21–147（127 aa）
Chain 2 21–147（127 aa）
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1ETA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 21–147（127 aa）
Chain 2 21–147（127 aa）
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1ETB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain 1 21–147（127 aa）
Chain 2 21–147（127 aa）
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1ETB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-->MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1993-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain 1 21–147（127 aa）
Chain 2 21–147（127 aa）
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1F41 CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTION Deposited 2000-06-07 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；40% PEG 550MME, 0.1M HEPES, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
Resolution 1.30 Å R-free 0.216
1F86 TRANSTHYRETIN THR119MET PROTEIN STABILISATION Deposited 2000-06-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：THR119MET Mutation：THR119MET T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.9；277 K；sodium citrate, 1,2,3 heptanetriol, ammonium sulphate, glycerol, methanol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.10 Å R-free 0.177
1F86 TRANSTHYRETIN THR119MET PROTEIN STABILISATION Deposited 2000-06-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：THR119MET Mutation：THR119MET T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.9；277 K；sodium citrate, 1,2,3 heptanetriol, ammonium sulphate, glycerol, methanol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
Resolution 1.10 Å R-free 0.177
1FH2 TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS Deposited 2000-07-31 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30M/T119M Mutation：V30M/T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.1；287 K；Ammonium Sulphate, Citrate Buffer, Glycerol, pH 5.1, VAPOR DIFFUSION, SITTING DROP, temperature 287K
Resolution 1.80 Å R-free 0.213
1FHN TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS Deposited 2000-08-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：T119M Mutation：T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.9；287 K；Ammonium Sulphate, Citrate Buffer, Glycerol, pH 4.9, VAPOR DIFFUSION, SITTING DROP, temperature 287K
Resolution 1.75 Å R-free 0.180
1G1O CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55S Deposited 2000-10-13 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；PEG 5000 MME, sodium citrate, ammonium sulphate, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.30 Å R-free 0.290
1GKO An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denatured Deposited 2001-08-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：YES Mutation：YES Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions MICROBATCH；pH 8.8；0.2 M MGCL2, 0.1 M TRIS BUFFER, PH 8.5, 30% W/V POLYETHYLENE GLYCOL 4000
Resolution 2.10 Å R-free 0.269
1ICT MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4) Deposited 2001-04-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions HANGMAN HANGING DROP CRYSTALLIZATION METHOD；pH 4.9；293 K；55% AMMONIUM SULFATE; 0.1 M PHOSPHATE BUFFER, pH 4.9, HANGMAN HANGING DROP CRYSTALLIZATION METHOD, temperature 293K
Resolution 3.00 Å R-free 0.289
1ICT MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4) Deposited 2001-04-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions HANGMAN HANGING DROP CRYSTALLIZATION METHOD；pH 4.9；293 K；55% AMMONIUM SULFATE; 0.1 M PHOSPHATE BUFFER, pH 4.9, HANGMAN HANGING DROP CRYSTALLIZATION METHOD, temperature 293K
Resolution 3.00 Å R-free 0.289
1III CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATURE Deposited 2001-04-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：TRANSTHYRETIN
Chain B 21–147（127 aa） Fragment：TRANSTHYRETIN
Mutation：Y114C Mutation：Y114C BME BETA-MERCAPTOETHANOL × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；2M ammonium sulphate, 0.1M sodium citrate, 2% PEG 200, 1% BME, pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
Resolution 2.00 Å R-free 0.235
1IIK CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATURE Deposited 2001-04-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：TRANSTHYRETIN
Chain B 21–147（127 aa） Fragment：TRANSTHYRETIN
Mutation：Y114C Mutation：Y114C BME BETA-MERCAPTOETHANOL × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME, pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
Resolution 2.00 Å R-free 0.239
1IJN Crystal structure of the transthyretin mutant TTR C10A/Y114C Deposited 2001-04-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：TRANSTHYRETIN
Chain B 21–147（127 aa） Fragment：TRANSTHYRETIN
Mutation：C10A/Y114C Mutation：C10A/Y114C BME BETA-MERCAPTOETHANOL × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME, pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
Resolution 1.70 Å R-free 0.237
1IJN Crystal structure of the transthyretin mutant TTR C10A/Y114C Deposited 2001-04-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa） Fragment：TRANSTHYRETIN
Chain B 21–147（127 aa） Fragment：TRANSTHYRETIN
Mutation：C10A/Y114C Mutation：C10A/Y114C BME BETA-MERCAPTOETHANOL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；40% PEG 550 monomethyl ether, 0.1M sodium citrate, 0.1M ammonium sulphate, 0.1% BME, pH 5.0, VAPOR DIFFUSION, HANGING DROP at 298K, temperature 298.0K
Resolution 1.70 Å R-free 0.237
1QAB The structure of human retinol binding protein with its carrier protein transthyretin reveals interaction with the carboxy terminus of RBP Deposited 1999-02-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded RTL RETINOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 3.20 Å R-free 0.403
1QWH a covalent dimer of transthyretin that affects the amyloid pathway Deposited 2003-09-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa）
Chain B 31–147（117 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.8；298 K；PEG 4000, 0.2 M Magnesium Nitrate , pH 5.8, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.36 Å R-free 0.222
1RLB RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN Deposited 1995-02-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Chain C 1–127（127 aa）
Chain D 1–127（127 aa）
Not recorded REA RETINOIC ACID × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 3.10 Å
1SOK Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212 Deposited 2004-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A108Y, L110E Mutation：A108Y, L110E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6；291 K；Tris, peg550mme, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
Resolution 1.60 Å R-free 0.242
1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A108Y, L110E Mutation：A108Y, L110E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
Resolution 2.10 Å R-free 0.246
1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：A108Y, L110E Mutation：A108Y, L110E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
Resolution 2.10 Å R-free 0.246
1SOQ Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 Deposited 2004-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：A108Y, L110E Mutation：A108Y, L110E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6；291 K；Tris, PEG550MME, ammonium sulfate, sodium citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K, pH 6.00
Resolution 2.10 Å R-free 0.246
1THA MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN SERUM TRANSTHYRETIN Deposited 1991-11-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Not recorded T33 3,3'-DEIODO-THYROXINE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å
1THC CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROXYAURONE COMPLEX Deposited 1992-04-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Not recorded FL9 3',5'-DIBROMO-2',4,4',6'-TETRAHYDROXY AURONE × 8 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.30 Å
1TLM STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROMS OF THE HUMAN SERUM TRANSTHYRETIN-MILRINONE COMPLEX Deposited 1992-12-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Not recorded MIL MILRINONE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
1TSH TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：VARIANT A60T Mutation：VARIANT A60T No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；PURIFIED PROTEIN (20MG/ML IN 25MM MONOBASIC SODIUM PHOSPHATE BUFFER, 0.15M NACL) WAS CRYSTALLIZED FROM 2.5M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.
Resolution 1.70 Å R-free 0.248
1TT6 The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-06-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SO4 SULFATE ION × 2 DES DIETHYLSTILBESTROL × 4 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.80 Å R-free 0.218
1TTA THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1TTB THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1TTC THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION Deposited 1992-11-02 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.70 Å
1TTR TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT Deposited 1996-04-11 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V122I Mutation：V122I No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.3；pH 5.3
Resolution 1.90 Å
1TTR TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT Deposited 1996-04-11 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V122I Mutation：V122I No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.3；pH 5.3
Resolution 1.90 Å
1TYR TRANSTHYRETIN COMPLEX WITH RETINOIC ACID Deposited 1995-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 9CR (9cis)-retinoic acid × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å
1TYR TRANSTHYRETIN COMPLEX WITH RETINOIC ACID Deposited 1995-05-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 9CR (9cis)-retinoic acid × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å
1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded ACT ACETATE ION × 2 DMS DIMETHYL SULFOXIDE × 2 GOL GLYCEROL × 2 DES DIETHYLSTILBESTROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.85 Å R-free 0.221
1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded GOL GLYCEROL × 1 DES DIETHYLSTILBESTROL × 2 CO3 CARBONATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.85 Å R-free 0.221
1TZ8 The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol Deposited 2004-07-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded GOL GLYCEROL × 2 DES DIETHYLSTILBESTROL × 4 CO3 CARBONATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Sodium Acetate (0.2M), Ammonium Sulfate (2.4M), glycerol (7%), pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.85 Å R-free 0.221
1U21 transthyretin with tethered inhibitor on one monomer. Deposited 2004-07-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；PEG 4000, calcium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.69 Å R-free 0.239
1X7S The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phe Deposited 2004-08-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：Y78F Mutation：Y78F No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.8；287 K；Ammonium Sulfate, Glycerol, Sodium Acetate, pH 4.8, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.55 Å R-free 0.238
1X7T Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effects Deposited 2004-08-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：R104H Mutation：R104H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.1；287 K；Ammonium Sulfate, Glycerol, Sodium Acetate, pH 5.1, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.60 Å R-free 0.252
1Y1D Crystal structure of transthyretin in complex with iododiflunisal Deposited 2004-11-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded FHI 2',4'-DIFLUORO-4-HYDROXY-5-IODO-1,1'-BIPHENYL-3-CARBOXYLIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；287 K；0.2M sodium citrate, 2.4M ammonium sulfate, 6% glycerol, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.70 Å R-free 0.222
1Z7J Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4ac) Deposited 2005-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded T4A 3,3',5,5'-TETRAIODOTHYROACETIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；48% ammonium sulfate, 0.l M phosphate buffer, pH 5.50, VAPOR DIFFUSION, HANGING DROP, temperature 4.0K
Resolution 2.20 Å R-free 0.217
1ZCR Crystal structure of human Transthyretin with bound iodide Deposited 2005-04-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IOD IODIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；291 K；Ammonium sulphate, 0.4M NaI, sodium citrate, PEG 200, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.80 Å R-free 0.238
1ZD6 Crystal structure of human transthyretin with bound chloride Deposited 2005-04-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CL CHLORIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；291 K；ammonium sulphate, sodium citrate, polyethyleneglycol, sodium chloride, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.90 Å R-free 0.221
2B14 The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Leu 55 Pro Deposited 2005-09-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L55P Mutation：L55P DNF 2,4-DINITROPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；287 K；PEG550, Hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 2.00 Å R-free 0.239
2B15 The crystal structure of 2,4-dinitrophenol in complex with human transthyretin Deposited 2005-09-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SO4 SULFATE ION × 4 DNF 2,4-DINITROPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.8；287 K；ammonium sulfate, glycerol, sodium acetate, pH 4.8, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.70 Å R-free 0.218
2B16 The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe Deposited 2005-09-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：Y78F Mutation：Y78F DNF 2,4-DINITROPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；Ammonium Sulfate, glycerol, sodium acetate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.75 Å R-free 0.236
2B77 Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID Deposited 2005-10-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 3CA 2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 mM EDTA, 10 mM sodium phosphate, 0.35-0.50 M ammonium sulfate - crystals were soaked with the inhibitor, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.70 Å R-free 0.238
2B9A Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxylic acid Deposited 2005-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded FBC 3',5'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；ammonium sulfate, 100 mM KCL, 1 mM EDTA, 10 mM sodium phosphate, soaked with the inhibitor, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.54 Å R-free 0.246
2F7I Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carboxylic Acid Deposited 2005-11-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 26C 2',6'-DIFLUOROBIPHENYL-4-CARBOXYLIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；AMMONIUM SULFATE, 100 MM KCL, 1 MM EDTA, 10 MM SODIUM PHOSPHATE, SOAKED WITH THE INHIBITOR, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.60 Å R-free 0.252
2F8I Human transthyretin (TTR) complexed with Benzoxazole Deposited 2005-12-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 205 2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 MM EDTA, 100 mM KCL, 10 MM SODIUM R 0.35 M AMMONIUM SULFATE - CRYSTALS WERE SOAKED WITH THE INHIBITOR, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, pH 7.00
Resolution 1.54 Å R-free 0.246
2F8I Human transthyretin (TTR) complexed with Benzoxazole Deposited 2005-12-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 205 2-(2,6-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；1 MM EDTA, 100 mM KCL, 10 MM SODIUM R 0.35 M AMMONIUM SULFATE - CRYSTALS WERE SOAKED WITH THE INHIBITOR, PH 7.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K, pH 7.00
Resolution 1.54 Å R-free 0.246
2FBR Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker) Deposited 2005-12-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 44C 4'-(4-{4-[(2-CARBOXYPHENYL)AMINO]PHENOXY}BUTOXY)-1,1'-BIPHENYL-4-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；TTR bivalent inhibitor complexes of 1:1 stoichiometry resulting from coassembly at 5-7 mg/mL (95-133 microM in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, 0.35-0.50 M ammonium sulfate equilibrated against 2 M ammonium sulfate, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.46 Å R-free 0.224
2FLM Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker) Deposited 2006-01-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6CA 4'-{6-[4-(2-CARBOXYPHENYLAMINO)-PHENOXY]-HEXYLOXY}-BIPHENYL-4-CARBOXYLIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；pH 7.00, VAPOR DIFFUSION, HANGING DROP
Resolution 1.65 Å R-free 0.234
2G3X Crystal structure of Transthyretin mutant I84S at acidic pH Deposited 2006-02-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I84S Mutation：I84S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.58 Å R-free 0.241
2G3Z Crystal structure of Transthyretin mutant I84A at low pH Deposited 2006-02-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I84A Mutation：I84A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.90 Å R-free 0.245
2G4E Crystal structure of transthyretin mutant I84A at neutral pH Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I84A Mutation：I84A No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.1M CaCl2, 14% PEG 400, 7.5% PEG 1500, 0.05M sodium Hepes, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 2.17 Å R-free 0.246
2G4G Crystal structure of human transthyretin at pH 4.6 Deposited 2006-02-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；15% PEG monomethyl ether, 0.1M ammonium sulphate, 50mM sodium acetate, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.233
2G5U Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl Deposited 2006-02-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded PCQ 3,5,3',5'-TETRACHLORO-BIPHENYL-4,4'-DIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；Crystals of recombinant WT TTR were obtained from protein solutions at 5 mg/ml (in 100 mM KCl, 100 mM phosphate [pH 7.4], 1 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drop experiments. The TTR ligand complexes were prepared from crystals soaked for 2 weeks with a 10-fold molar excess , pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.80 Å R-free 0.220
2G9K Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4',5-Pentachlorobiphenyl Deposited 2006-03-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded NE1 2',3,3',4',5-PENTACHLOROBIPHENYL-4-OL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；CRYSTALLIZATION CONDITIONS: CRYSTALS OF RECOMBINANT WT TTR WERE OBTAINED FROM PROTEIN SOLUTIONS AT 5 MG/ML (IN 100 MM KCL, 100 MM PHOSPHATE [PH 7.4], 1 M AMMONIUM SULFATE) EQUILIBRATED AGAINST 2 M AMMONIUM SULFATE IN HANGING DROP EXPERIMENTS. THE TTR LIGAND COMPLEXES WERE PREPARED FROM CRYSTALS SOAKED FOR 2 WEEKS WITH A 10-FOLD MOLAR EXCESS , pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.85 Å R-free 0.257
2GAB Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-tetrachlorobiphenyl Deposited 2006-03-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded NE2 3,3',4',5-TETRACHLOROBIPHENYL-4-OL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；CRYSTALLIZATION CONDITIONS: CRYSTALS OF RECOMBINANT WT TTR WERE OBTAINED FROM PROTEIN SOLUTIONS AT 5 MG/ML (IN 100 MM KCL, 100 MM PHOSPHATE [PH 7.4], 1 M AMMONIUM SULFATE) EQUILIBRATED AGAINST 2 M AMMONIUM SULFATE IN HANGING DROP EXPERIMENTS. THE TTR LIGAND COMPLEXES WERE PREPARED FROM CRYSTALS SOAKED FOR 2 WEEKS WITH A 10-FOLD MOLAR EXCESS , PH 7.00, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K , VAPOR DIFFUSION, HANGING DROP
Resolution 1.85 Å R-free 0.238
2H4E Crystal structure of Cys10 sulfonated transthyretin Deposited 2006-05-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；0.2M sodium acetate, 2.0 M ammonium sulphate, 6 % glycerol, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.45 Å R-free 0.198
2NBO Solution structure of the F87M/L110M variant of transthyretin in the monomeric state Deposited 2016-03-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 21–147（127 aa）
Mutation：F107M, L130M No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 50
NMR sample composition 0.3-0.7 mM [U-13C; U-15N] M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition 0.7 mM [U-13C; U-15N] M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 100% D2O | 100% D2O
Resolution not provided
2NBP Solution structure of the T119M variant of transthyretin in its monomeric state Deposited 2016-03-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 21–147（127 aa）
Mutation：F107M, L130M, T139M No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient
NMR sample composition 0.6-1.2 mM [U-13C; U-15N] T119M M-TTR, 50 mM MES, 100 mM sodium chloride, 5 mM DTT, 0.1 mM DSS, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
2NOY Crystal structure of transthyretin mutant I84S at PH 7.5 Deposited 2006-10-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I84S Mutation：I84S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1M CaCl2, 14%(w/v) PEG 400, 7.5%(w/v) PEG 1500, 0.05M sodium Hepes (pH 7.5), VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.80 Å R-free 0.251
2PAB STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS Deposited 1977-09-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å
2PAB STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS Deposited 1977-09-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–127（127 aa）
Chain B 1–127（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.80 Å
2QEL Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated protein Deposited 2007-06-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S Mutation：G53S,E54D,L55S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；0.1M Tris, 2.4M Ammonium sulphate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.29 Å R-free 0.289
2QGB Human transthyretin (TTR) in Apo-form Deposited 2007-06-28 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.40 Å R-free 0.188
2QGC Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazole Deposited 2007-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded MR4 4-(1,3-BENZOXAZOL-2-YL)-2,6-DIMETHYLPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.30 Å R-free 0.174
2QGD Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazole Deposited 2007-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded MR5 4-(1,3-BENZOXAZOL-2-YL)-2,6-DIBROMOPHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.50 Å R-free 0.199
2QGE Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazole Deposited 2007-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded MR6 2-(3,5-DIMETHYLPHENYL)-1,3-BENZOXAZOLE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol., VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.45 Å R-free 0.200
2ROX TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4) Deposited 1996-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SO4 SULFATE ION × 2 T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å
2ROY TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINE Deposited 1996-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded P28 3',5'-DINITRO-N-ACETYL-L-THYRONINE × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.20 Å
2TRH TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：VARIANT R10C Mutation：VARIANT R10C No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；PURIFIED PROTEIN (20MG/ML IN 100MM TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM\\ 2.25M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5 AT ROOM TEMPERATURE.\\, pH 6.5
Resolution 1.90 Å R-free 0.299
2TRY TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION Deposited 1996-10-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：VARIANT S77Y Mutation：VARIANT S77Y No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；PURIFIED PROTEIN (25MG/ML IN 100MM TRIS BUFFER, PH 7.5) WAS CRYSTALLIZED FROM 1.5M AMMONIUM SULFATE, 100MM CITRATE BUFFER, PH 5.5, AT ROOM TEMPERATURE., pH 6.5
Resolution 2.00 Å R-free 0.310
2WQA Complex of TTR and RBP4 and Oleic Acid Deposited 2009-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded SO4 SULFATE ION × 11 OLA OLEIC ACID × 2 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.85 Å R-free 0.253
3A4D Crystal structure of Human Transthyretin (wild-type) Deposited 2009-07-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SO4 SULFATE ION × 4 GOL GLYCEROL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.00 Å R-free 0.229
3A4E Crystal structure of Human Transthyretin (E54G) Deposited 2009-07-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded GOL GLYCEROL × 6 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200 mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.70 Å R-free 0.238
3A4F Crystal Structure of Human Transthyretin (E54K) Deposited 2009-07-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded GOL GLYCEROL × 10 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.3；293 K；200mM citrate, 3M ammonium sulfate, pH 5.3, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.99 Å R-free 0.223
3B56 Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acid Deposited 2007-10-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded DIU 2-HYDROXY-3,5-DIIODO-BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；287 K；200mM acetate buffer, 2.2M ammonium sulfate, 7% glycerol, pH 5.0, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.55 Å R-free 0.214
3BSZ Crystal structure of the transthyretin-retinol binding protein-Fab complex Deposited 2007-12-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded RTL RETINOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；295 K；2.35M ammonium phosphate, 10mM sodium citrate, 10mM beta-mercaptoethanol, pH 5.0, VAPOR DIFFUSION, SITTING DROP, temperature 295K
Resolution 3.38 Å R-free 0.312
3BT0 Crystal structure of transthyretin variant V20S Deposited 2007-12-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V20S Mutation：V20S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；295 K；0.066M CaCl2, 19% (w/v) PEG 400, 0.13M sodium Hepes , pH 7.5, VAPOR DIFFUSION, temperature 295K
Resolution 1.59 Å R-free 0.229
3CBR Crystal structure of human Transthyretin (TTR) at pH3.5 Deposited 2008-02-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 3.5；289 K；5-7 mg/ml protein, 0.1 M sodium acetate, 20 % PEG 3350, 0.3-0.5 M ammonium sulfate equilibrated against 2.0M ammonium sulfate, pH 3.5, VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.70 Å R-free 0.260
3CFM Crystal structure of the apo form of human wild-type transthyretin Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa） Fragment：UNP residue 30-147
Chain B 30–147（118 aa） Fragment：UNP residue 30-147
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Mother liquor: 100 mM tris pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop 1 uL mother liquor + 1 uL TTR 10 mg/mL; crystals appeared in about 5 days, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.60 Å R-free 0.218
3CFM Crystal structure of the apo form of human wild-type transthyretin Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–147（118 aa） Fragment：UNP residue 30-147
Chain B 30–147（118 aa） Fragment：UNP residue 30-147
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；Mother liquor: 100 mM tris pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop 1 uL mother liquor + 1 uL TTR 10 mg/mL; crystals appeared in about 5 days, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.60 Å R-free 0.218
3CFN Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa） Fragment：UNP residue 30-147
Chain B 30–147（118 aa） Fragment：UNP residue 30-147
Not recorded 2AN 8-ANILINO-1-NAPHTHALENE SULFONATE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop consisting of 1 uL mother liquor and 1 uL wtTTR 10 mg/mL; crystals appeared in about 5 days; complex obtained by soaking in mother liquor supplemented with saturating amount of ligand., VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.87 Å R-free 0.245
3CFN Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–147（118 aa） Fragment：UNP residue 30-147
Chain B 30–147（118 aa） Fragment：UNP residue 30-147
Not recorded 2AN 8-ANILINO-1-NAPHTHALENE SULFONATE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH 7.5, 100 mM KCl, 20 % v/v PEG 400; drop consisting of 1 uL mother liquor and 1 uL wtTTR 10 mg/mL; crystals appeared in about 5 days; complex obtained by soaking in mother liquor supplemented with saturating amount of ligand., VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.87 Å R-free 0.245
3CFQ Crystal structure of human wild-type transthyretin in complex with diclofenac Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa） Fragment：UNP residues 30-147
Chain B 30–147（118 aa） Fragment：UNP residues 30-147
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH7.5, 100 mM KCl, 20 % v/v PEG400; drop: 1 uL mother liquor + 1 uL wtTTR 10 mg/mL; crystals appeared in 5 days; complexes obtained by soaking in mother liquor supplemented with saturating amount of diclofenac, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.09 Å R-free 0.249
3CFQ Crystal structure of human wild-type transthyretin in complex with diclofenac Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–147（118 aa） Fragment：UNP residues 30-147
Chain B 30–147（118 aa） Fragment：UNP residues 30-147
Not recorded DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；mother liquor: 100 mM Tris, pH7.5, 100 mM KCl, 20 % v/v PEG400; drop: 1 uL mother liquor + 1 uL wtTTR 10 mg/mL; crystals appeared in 5 days; complexes obtained by soaking in mother liquor supplemented with saturating amount of diclofenac, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.09 Å R-free 0.249
3CFT Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa） Fragment：UNP residues 30-147
Chain B 30–147（118 aa） Fragment：UNP residues 30-147
Not recorded 5NS 5-aminonaphthalene-1-sulfonic acid × 6 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.87 Å R-free 0.239
3CFT Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate Deposited 2008-03-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–147（118 aa） Fragment：UNP residues 30-147
Chain B 30–147（118 aa） Fragment：UNP residues 30-147
Not recorded 5NS 5-aminonaphthalene-1-sulfonic acid × 3 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.87 Å R-free 0.239
3CN0 Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ1 2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.189
3CN0 Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ1 2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.189
3CN1 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ2 2,6-dibromo-4-[(E)-2-phenylethenyl]phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.188
3CN1 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ2 2,6-dibromo-4-[(E)-2-phenylethenyl]phenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.188
3CN2 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ3 3,5-dibromobiphenyl-4-ol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.197
3CN2 Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ3 3,5-dibromobiphenyl-4-ol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.52 Å R-free 0.197
3CN3 Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ4 2,6-dibromo-4-phenoxyphenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.80 Å R-free 0.216
3CN3 Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ4 2,6-dibromo-4-phenoxyphenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.80 Å R-free 0.216
3CN4 Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ5 N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.40 Å R-free 0.202
3CN4 Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide Deposited 2008-03-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LJ5 N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.40 Å R-free 0.202
3CXF Crystal structure of transthyretin variant Y114H Deposited 2008-04-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：Y114H Mutation：Y114H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.6；295 K；0.066M CaCl2, 19 % (w/v) PEG 400, 0.13M sodium Hepes, pH 5.6, VAPOR DIFFUSION, temperature 295K
Resolution 2.30 Å R-free 0.281
3CXF Crystal structure of transthyretin variant Y114H Deposited 2008-04-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：Y114H Mutation：Y114H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 5.6；295 K；0.066M CaCl2, 19 % (w/v) PEG 400, 0.13M sodium Hepes, pH 5.6, VAPOR DIFFUSION, temperature 295K
Resolution 2.30 Å R-free 0.281
3D2T Human transthyretin (ttr) complexed with diflunisal Deposited 2008-05-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；5-7 mg/ml protein, in 0.3 M AMMONIUM SULFATE, 100 MM KCL, 1 MM EDTA, 10 MM SODIUM PHOSPHATE equilibrated against 2 M ammonium sulfate; SOAKED WITH THE INHIBITOR., pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.85 Å R-free 0.235
3D7P Crystal structure of human Transthyretin (TTR) at pH 4.0 Deposited 2008-05-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4；289 K；TTR pH 4.0 crystals were grown in the presence of 0.1 M sodium acetate (pH 4.0), 100 mM KCl, 1 mM EDTA and 0.3-0.5 M ammonium sulfate which was equilibrated against 2 M ammonium sulfate in hanging drop, VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.72 Å R-free 0.249
3DGD Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 Deposited 2008-06-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：Y Mutation：Y Mutation：Y Mutation：Y ZN ZINC ION × 15 ACT ACETATE ION × 12 GOL GLYCEROL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 4,6; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, PH 4.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K, pH 4.60
Resolution 1.38 Å R-free 0.202
3DID Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soaked Deposited 2008-06-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：Y Mutation：Y Mutation：Y Mutation：Y ZN ZINC ION × 12 ACT ACETATE ION × 6 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 4,6; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, pH 4.60, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.78 Å R-free 0.242
3DJR CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L58H Mutation：L58H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes, pH 7.5, VAPOR DIFFUSION, temperature 295K
Resolution 2.02 Å R-free 0.228
3DJS Crystal structure of transthyretin variant L58H at acidic pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L58H Mutation：L58H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 2000, 0.1M NaAc, 0.2M Am2SO4 , pH 4.6, VAPOR DIFFUSION, temperature 295K
Resolution 1.80 Å R-free 0.217
3DJT Crystal structure of transthyretin variant V30M at acidic pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 2000, 0.1M NaAc, 0.2M Am2SO4 , pH 4.6, VAPOR DIFFUSION, temperature 295K
Resolution 2.30 Å R-free 0.253
3DJZ Crystal structure of transthyretin variant L55P at neutral pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes , pH 7.5, VAPOR DIFFUSION, temperature 295K
Resolution 1.82 Å R-free 0.219
3DK0 Crystal structure of transthyretin variant L55P at acidic pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；295 K；32% PEG 400, 0.05-0.2M CaCl2, 0.1M NaHepes , pH 4.6, VAPOR DIFFUSION, temperature 295K
Resolution 1.87 Å R-free 0.223
3DK2 Crystal structure of transthyretin variant Y114H at acidic pH Deposited 2008-06-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：Y114H Mutation：Y114H No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；295 K；Na Citrate 0.1 M, Ammonium sulfate 2M , pH 4.6, VAPOR DIFFUSION, temperature 295K
Resolution 2.35 Å R-free 0.247
3DO4 Crystal structure of transthyretin variant T60A at acidic pH Deposited 2008-07-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain D 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Mutation：T60A Mutation：T60A Mutation：T60A Mutation：T60A ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；298 K；15% PEG 4000, 0.05M NaAcetate, 0.1M AmmoniumAcetate , pH 4.6, VAPOR DIFFUSION, temperature 298K
Resolution 2.40 Å R-free 0.267
3DO4 Crystal structure of transthyretin variant T60A at acidic pH Deposited 2008-07-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain E 21–147（127 aa）
Mutation：T60A Mutation：T60A Mutation：T60A Mutation：T60A ACT ACETATE ION × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 4.6；298 K；15% PEG 4000, 0.05M NaAcetate, 0.1M AmmoniumAcetate , pH 4.6, VAPOR DIFFUSION, temperature 298K
Resolution 2.40 Å R-free 0.267
3ESN Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide Deposited 2008-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded DZ1 N-(3,5-dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.35 Å R-free 0.202
3ESO Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamide Deposited 2008-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded DZ2 2,5-dichloro-N-(3,5-dibromo-4-hydroxyphenyl)benzamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.31 Å R-free 0.204
3ESP Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenzamide Deposited 2008-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded DZ3 N-(3,5-dibromo-4-hydroxyphenyl)-4-hydroxy-3,5-dimethylbenzamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.31 Å R-free 0.201
3FC8 Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMe Deposited 2008-11-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa）
Chain B 21–144（124 aa）
Not recorded IFA METHYL N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINATE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.2；287 K；2.0 M ammonium sulfate, 7% glycerol and 0.2 M sodium acetate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.85 Å R-free 0.210
3FCB Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH Deposited 2008-11-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa）
Chain B 21–144（124 aa）
Not recorded IFB N-[(2',4'-DIFLUORO-4-HYDROXY-5-IODOBIPHENYL-3-YL)CARBONYL]-BETA-ALANINE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；287 K；2.2 M ammonium sulphate, 7% glycerol and 0.2 M sodium acetate, pH 5.4, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 1.80 Å R-free 0.226
3GLZ Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11) Deposited 2009-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 1BD 3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. TTR:ligand complexes were prepared from crystals soaked with a tenfold molar excess of ligand for more than two weeks., VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.78 Å R-free 0.273
3GLZ Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11) Deposited 2009-03-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 1BD 3-[({(1E)-[2-(trifluoromethyl)phenyl]methylidene}amino)oxy]propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；289 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. TTR:ligand complexes were prepared from crystals soaked with a tenfold molar excess of ligand for more than two weeks., VAPOR DIFFUSION, HANGING DROP, temperature 289K
Resolution 1.78 Å R-free 0.273
3GPS Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5 Deposited 2009-03-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain C 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain D 21–147（127 aa） Fragment：UNP residues 21 to 147
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M ZN ZINC ION × 12 ACT ACETATE ION × 10 GOL GLYCEROL × 7 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.78 Å R-free 0.254
3GRB Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5 Deposited 2009-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain C 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain D 21–147（127 aa） Fragment：UNP residues 21 to 147
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M ZN ZINC ION × 12 GOL GLYCEROL × 7 ACT ACETATE ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 6.5; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.75 Å R-free 0.260
3GRG Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5 Deposited 2009-03-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain C 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain D 21–147（127 aa） Fragment：UNP residues 21 to 147
Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M Mutation：F87M,L110M ZN ZINC ION × 12 ACT ACETATE ION × 7 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；ZINC ACETATE 0.2 M, SODIUM CITRATE 0.1 M, AMMONIUM SULFATE 2,0M, PH 7.5; CRYSTALS WERE SOAKED IN MOTHER LIQUOR SUPPLEMENTED WITH 10 % GLYCEROL BEFORE FREEZING IN LIQUID NITROGEN, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.90 Å R-free 0.255
3GS0 Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks., VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.85 Å R-free 0.269
3GS0 Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks., VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.85 Å R-free 0.269
3GS4 Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.78 Å R-free 0.278
3GS4 Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.78 Å R-free 0.278
3GS7 Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 8BD 3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.80 Å R-free 0.266
3GS7 Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13) Deposited 2009-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa） Fragment：UNP residues 21 to 147
Chain B 21–147（127 aa） Fragment：UNP residues 21 to 147
Not recorded 8BD 3-({[(1Z)-(2-methoxyphenyl)methylidene]amino}oxy)propanoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；290 K；Crystals of wt-TTR were obtained from 5-7 mg/mL protein solutions (in 100 mM KCl, 1 mM EDTA, 10 mM sodium phosphate, pH 7.0, 0.3 M ammonium sulfate) equilibrated against 2 M ammonium sulfate in hanging drops. All TTR:ligand complexes were prepared from crystals soaked with a ten fold molar excess of ligand for more than three weeks. , VAPOR DIFFUSION, HANGING DROP, temperature 290K
Resolution 1.80 Å R-free 0.266
3HJ0 Transthyretin in complex with a covalent small molecule kinetic stabilizer Deposited 2009-05-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 30-147
Chain B 21–147（127 aa） Fragment：UNP residues 30-147
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) A93 4-fluorophenyl 3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoate × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.34 Å R-free 0.182
3I9A Crystal structure of human transthyretin variant A25T - #1 Deposited 2009-07-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A25T Mutation：A25T PGE TRIETHYLENE GLYCOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL TTR + 1 uL well solution composed by 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.65 Å R-free 0.227
3I9I Crystal structure of human transthyretin variant A25T - #2 Deposited 2009-07-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Mutation：A45T Mutation：A45T PGE TRIETHYLENE GLYCOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.237
3I9I Crystal structure of human transthyretin variant A25T - #2 Deposited 2009-07-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Mutation：A45T Mutation：A45T PGE TRIETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I#14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.237
3I9P Crystal structure of human transthyretin - wild type Deposited 2009-07-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL wtTTR + 1 uL well solution - 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I #14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.255
3I9P Crystal structure of human transthyretin - wild type Deposited 2009-07-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1 uL 5 mg/mL wtTTR + 1 uL well solution - 0.1 M Hepes sodium pH 7.5, 28 % PEG 400, 0.2 calcium chloride dihydrate (Hampton's Crystal Screen I #14), VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.255
3IMR Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenol Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW1 2,6-dibromo-4-[(E)-2-(2,6-dichlorophenyl)ethenyl]phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.70 Å R-free 0.217
3IMS Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenol Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW2 2,6-dibromo-4-[2-(2,6-dichlorophenyl)ethyl]phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.40 Å R-free 0.197
3IMT Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenol Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW3 4-[(E)-2-(4-aminophenyl)ethenyl]-2,6-dibromophenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.40 Å R-free 0.190
3IMU Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoaniline Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW4 4-[(E)-2-(3-aminophenyl)ethenyl]-2,6-dibromoaniline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.40 Å R-free 0.191
3IMV Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW5 4-[(E)-2-(4-aminophenyl)ethenyl]-2,6-dibromoaniline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.47 Å R-free 0.201
3IMW Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)aniline Deposited 2009-08-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IW6 2,6-dibromo-4-[(E)-2-(2,6-dimethoxyphenyl)ethenyl]aniline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.31 Å R-free 0.196
3IPB Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker). Deposited 2009-08-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded JZD 2,2'-{undecane-1,11-diylbis[oxy(3,5-dichlorobenzene-4,1-diyl)imino]}dibenzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；25- 32% v/v PEG550-monomethyl ether, 70 mM NaAc buffer pH 4-5 and 100 mM NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.229
3IPE Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker). Deposited 2009-08-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded JZE 2,2'-{heptane-1,7-diylbis[oxy(3,5-dichlorobenzene-4,1-diyl)imino]}dibenzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 4.5；298 K；25- 32% v/v PEG550-monomethyl ether, 70 mM NaAc buffer pH 4-5 and 100 mM NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.40 Å R-free 0.196
3KGS V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5 Deposited 2009-10-29 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 20-147
Chain B 21–147（127 aa） Fragment：UNP residues 20-147
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.80 Å R-free 0.248
3KGT V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5 Deposited 2009-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Mutation：V30M Mutation：V30M GEN GENISTEIN × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.95 Å R-free 0.241
3KGU Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5 Deposited 2009-10-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded GEN GENISTEIN × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.85 Å R-free 0.234
3M1O Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acid Deposited 2010-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CJZ 2-[(3,5-dichloro-4-hydroxyphenyl)amino]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；25- 32% V/V PEG550-MONOMETHYL ETHER, 70 MM NAAC BUFFER PH 4-5 AND 100 MM NACL, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.20 Å R-free 0.171
3NEE Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1) Deposited 2010-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Chain B 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Not recorded B72 {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid × 4 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.55 Å R-free 0.217
3NEO Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24) Deposited 2010-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Chain B 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Not recorded G24 [4-(3-BENZYL-4-HYDROXYBENZYL)-3,5-DIMETHYLPHENOXY]ACETIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 2.00 Å R-free 0.220
3NES V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1) Deposited 2010-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Chain B 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Mutation：V30M Mutation：V30M B72 {4-[4-hydroxy-3-(1-methylethyl)benzyl]-3,5-dimethylphenoxy}acetic acid × 4 GOL GLYCEROL × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.75 Å R-free 0.223
3NEX V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24) Deposited 2010-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Chain B 30–145（116 aa） Fragment：UNP RESIDUES 30-145
Mutation：V30M Mutation：V30M GOL GLYCEROL × 4 G24 [4-(3-BENZYL-4-HYDROXYBENZYL)-3,5-DIMETHYLPHENOXY]ACETIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M CaCl2, 0.1 M HEPES pH 7.5, 28% PEG 400, vapor diffusion, hanging drop, temperature 293K
Resolution 1.70 Å R-free 0.207
3NG5 Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG) Deposited 2010-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30M Mutation：V30M KDH (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate × 6 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；pH 5.3；293 K；200MM CITRATE, 3M AMMONIUM SULFATE, pH 5.3, EVAPORATION, temperature 293K
Resolution 1.70 Å R-free 0.227
3OZK Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4) Deposited 2010-09-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A25T Mutation：A25T T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes sodium pH 7.5, 28% PEG 400, 0.2 calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 293K, complex obtained by soaking crystal with ligand.
Resolution 1.90 Å R-free 0.236
3OZL Crystal structure of human transthyretin variant A25T in complex with flufenamic acid. Deposited 2010-09-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A25T Mutation：A25T FLF 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1 M Hepes sodium pH 7.5, 28% PEG 400, 0.2 calcium chloride dihydrate, VAPOR DIFFUSION, HANGING DROP, temperature 293K, soaking for 1 h with ligand.
Resolution 1.90 Å R-free 0.247
3P3R Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone Deposited 2010-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 3M1 (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.25 Å R-free 0.180
3P3S Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimidazolidin-4-one Deposited 2010-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 3M2 (5Z)-2-amino-5-(3,5-dibromo-4-hydroxybenzylidene)-1-methyl-1,5-dihydro-4H-imidazol-4-one × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.60 Å R-free 0.232
3P3T Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazole Deposited 2010-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 3M3 4-[3-(2-fluorophenoxy)propyl]-3,5-dimethyl-1H-pyrazole × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.45 Å R-free 0.199
3P3U Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole Deposited 2010-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 3M4 4-[5-(2-ethoxyphenyl)-1,2,4-oxadiazol-3-yl]pyridine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.50 Å R-free 0.198
3SSG Structure of transthyretin L55P in complex with Zn Deposited 2011-07-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Mutation：L55P ZN ZINC ION × 8 CAC CACODYLATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；287 K；3% w/v PEG 8000, 0.1M cacodylate pH 6.5, 5 mM Zn acetate, VAPOR DIFFUSION, HANGING DROP, temperature 287K
Resolution 2.00 Å R-free 0.247
3TCT Structure of wild-type TTR in complex with tafamidis Deposited 2011-08-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：unp residues 21-147
Chain B 21–147（127 aa） Fragment：unp residues 21-147
Not recorded 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298.0K
Resolution 1.30 Å R-free 0.192
3TFB Transthyretin natural mutant A25T Deposited 2011-08-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Mutation：A45T Mutation：A45T No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.03 Å R-free 0.239
3U2I X-ray crystal structure of human Transthyretin at room temperature Deposited 2011-10-03 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 32–147（116 aa） Fragment：UNP residues 32-147
Chain B 32–147（116 aa） Fragment：UNP residues 32-147
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；2.0M tri-ammonium citrate(pD7.4), 0.4M MgCl2, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.70 Å R-free 0.239
3U2J Neutron crystal structure of human Transthyretin Deposited 2011-10-03 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 32–147（116 aa） Fragment：UNP residues 32-147
Chain B 32–147（116 aa） Fragment：UNP residues 32-147
Not recorded No recorded non-water small molecule NEUTRON DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；1.85M tri-ammonium citrate, pD7.4, 0.4M MgCl2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.00 Å R-free 0.272
3W3B Crystal structure of wild-type human transthyretin Deposited 2012-12-19 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.235
4ABQ CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1 Deposited 2011-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa） Fragment：RESIDUES 21-144
Chain B 21–144（124 aa） Fragment：RESIDUES 21-144
Not recorded 4V2 3-(5-MERCAPTO-1,3,4-OXADIAZOL-2-YL)-PHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.70 Å R-free 0.242
4ABU CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2 Deposited 2011-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa） Fragment：RESIDUES 21-144
Chain B 21–144（124 aa） Fragment：RESIDUES 21-144
Not recorded FT1 4-(2,4-dichlorophenoxy)-3-hydroxybenzaldehyde × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.86 Å R-free 0.254
4ABV CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3 Deposited 2011-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa） Fragment：RESIDUES 21-144
Chain B 21–144（124 aa） Fragment：RESIDUES 21-144
Not recorded FT2 5-(chloromethyl)-2-(2,4-dichlorophenoxy)phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.80 Å R-free 0.246
4ABW Crystal Structure of Transthyretin in Complex With Ligand C-6 Deposited 2011-12-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa） Fragment：RESIDUES 21-144
Chain B 21–144（124 aa） Fragment：RESIDUES 21-144
Not recorded 42M [4-(2,4-dinitrophenoxy)-3-methoxyphenyl]methanol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.70 Å R-free 0.257
4AC2 CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7 Deposited 2011-12-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–144（124 aa） Fragment：RESIDUES 21-144
Chain B 21–144（124 aa） Fragment：RESIDUES 21-144
Not recorded 43F 2,4-DICHLORO-1-[4-(CHLOROMETHYL)-2-METHOXYPHENOXY]BENZENE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.81 Å R-free 0.236
4AC4 CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18 Deposited 2011-12-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded HKA 3-METHOXY-4-PHENOXYBENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.80 Å R-free 0.258
4ACT CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17 Deposited 2011-12-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded FT0 3-hydroxy-4-phenoxybenzaldehyde × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.80 Å R-free 0.265
4ANK Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two T4 binding sites. Deposited 2012-03-20 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；POTASSIUM CHLORIDE, POTASSIUM PHOSPHATE, AMMONIUM SULFATE, PH 7.4, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
Resolution 1.70 Å R-free 0.250
4D7B Structure of human transthyretin in complex with Tolcapone Deposited 2014-11-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded TCW Tolcapone × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.15 Å R-free 0.201
4DER Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API) Deposited 2012-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Not recorded AGI 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one × 4 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.235
4DES Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR) Deposited 2012-01-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Not recorded 57D chrysin × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.75 Å R-free 0.226
4DET Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE) Deposited 2012-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Not recorded KMP 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.05 Å R-free 0.223
4DEU Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR) Deposited 2012-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Not recorded EDO 1,2-ETHANEDIOL × 20 NAR NARINGENIN × 4 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.60 Å R-free 0.213
4DEW Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT) Deposited 2012-01-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M calcium chloride, 0.1 M HEPES, pH 7.5, 28% PEG400, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.90 Å R-free 0.199
4FI6 Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 0U7 3-[5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
Resolution 1.46 Å R-free 0.182
4FI7 Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 0UA 3-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
Resolution 1.40 Å R-free 0.205
4FI8 Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide Deposited 2012-06-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 0UC 4-bromo-3-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]benzenesulfonyl fluoride × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
Resolution 1.22 Å R-free 0.197
4HIQ The Structure of V122I Mutant Transthyretin in Complex with AG10 Deposited 2012-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V122I Mutation：V122I 16V 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.18 Å R-free 0.186
4HIS The Structure of V122I Mutant Transthyretin in Complex with Tafamidis Deposited 2012-10-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V122I Mutation：V122I 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.20 Å R-free 0.172
4HJS Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)ethanesulfonamide Deposited 2012-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded 18J N-{4-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}ethanesulfonamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.22 Å R-free 0.224
4HJT Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)phenyl)propionamide Deposited 2012-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 18A N-{4-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}propanamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.45 Å R-free 0.187
4HJU Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamide Deposited 2012-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 16L N-{3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]phenyl}prop-2-enamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；THE WT-TTR WAS CONCENTRATED TO 4 MG/ML IN 10 MM NAPI, 100 MM KCL, AT PH 7.6 AND CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH INHIBITORS USING THE VAPOR-DIFFUSION SITTING DROP METHOD, CRYSTALS WERE GROWN FROM 1.395 M SODIUM CITRATE, 3.5% V/V GLYCEROL AT PH 5.5. THE CRYSTALS WERE FROZEN USING A CRYO-PROTECTANT SOLUTION OF 1.395 M SODIUM CITRATE, PH 5.5, CONTAINING 10% V/V GLYCEROL, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.35 Å R-free 0.188
4I85 Crystal structure of transthyretin in complex with CHF5074 at neutral pH Deposited 2012-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Chain B 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Not recorded H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.67 Å R-free 0.230
4I87 Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pH Deposited 2012-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Chain B 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Mutation：I84S Mutation：I84S H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；15% (w/v) PEG 2000 monomethylether, 0.1 M ammonium sulfate, 0.05 M sodium acetate buffer, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.69 Å R-free 0.211
4I89 Crystal structure of transthyretin in complex with diflunisal at acidic pH Deposited 2012-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Chain B 21–147（127 aa） Fragment：Transthyretin (unp residues 21-147)
Mutation：I84S Mutation：I84S 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；15% (w/v) PEG 2000 monomethylether, 0.1 M ammonium sulfate, 0.05 M sodium acetate buffer, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.69 Å R-free 0.222
4IIZ Crystal structure of wild-type human transthyretin in complex with lumiracoxib Deposited 2012-12-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LUR {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.10 Å R-free 0.240
4IK6 Crystal structure of human transthyretin in complex with lumiracoxib Deposited 2012-12-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LUR {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.00 Å R-free 0.238
4IK7 Crystal structure of human transthyretin in complex with indomethacin Deposited 2012-12-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IMN INDOMETHACIN × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.244
4IKI Crystal structure of wild-type human transthyretin in complex with indomethacin Deposited 2012-12-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IMN INDOMETHACIN × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；291 K；10mg/mL wtTTR, 22% peg 400, 100mM Tris pH 7.4, 100mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.00 Å R-free 0.235
4IKJ Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；10mg/mL wtTTR, 0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400 (Hampton Research's Crystal Screen I, #14), VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 2.10 Å R-free 0.257
4IKK Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；10mg/mL wtTTR, 0.2M Calcium chloride, 0.1M HEPES sodium pH 7.5, 28% v/v Polyethylene glycol 400 (Hampton Research's Crystal Screen I, #14), VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.90 Å R-free 0.250
4IKL Crystal structure of wild-type human transthyretin in complex with sulindac Deposited 2012-12-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SUZ [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；291 K；10mg/mL wtTTR, 22% peg 400, 100mM Tris pH 7.4, 100 mM KCl, VAPOR DIFFUSION, HANGING DROP, temperature 291K
Resolution 1.90 Å R-free 0.244
4KY2 Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethylstyryl)-4-methyl-2H-chromen-2-one Deposited 2013-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 1W3 7-hydroxy-3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]-4-methyl-2H-chromen-2-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.13 Å R-free 0.174
4L1S Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzamide Deposited 2013-06-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 1W4 S-(4-fluorophenyl) 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzenecarbothioate × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0, VAPOR DIFFUSION, SITTING DROP
Resolution 1.50 Å R-free 0.185
4L1T Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acid Deposited 2013-06-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
Resolution 1.16 Å R-free 0.188
4MAS High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1,1'-biphenyl]-4,4'diol Deposited 2013-08-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded PCQ 3,5,3',5'-TETRACHLORO-BIPHENYL-4,4'-DIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；4 mg/ML wt-TTR in 10 mM sodium phosphate, 100 mM potassium chloride, pH 7.6, co-crystallized with inhibitor, crystallization solution: 1.395 M sodium citrate, 3.5% v/v glycerol, pH 5.5, cryoprotectant: 1.395 M sodium citrate, pH 5.5, 10% v/v glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.22 Å R-free 0.173
4MRB Wild Type Human Transthyretin pH 7.5 Deposited 2013-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；293 K；100mM HEPES, 200mM CaCl2, 28% PEG400 v/v, pH 7.5, VAPOR DIFFUSION, temperature 293K
Resolution 1.27 Å R-free 0.209
4MRC Human Transthyretin Ser52Pro Mutant Deposited 2013-09-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 22–147（126 aa） Fragment：UNP residues 22-147
Chain B 22–147（126 aa） Fragment：UNP residues 22-147
Mutation：S52P Mutation：S52P CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 7.5；293 K；100mM HEPES, 200mM CaCl2, 28% PEG400 v/v, pH 7.5, VAPOR DIFFUSION, temperature 293K
Resolution 1.54 Å R-free 0.228
4N85 Crystal structure of human transthyretin Deposited 2013-10-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded CA CALCIUM ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；34-40% PEG 400, 0.4M CaCl2, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.60 Å R-free 0.239
4N86 Crystal structure of human transthyretin complexed with glabridin Deposited 2013-10-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded GBJ 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol × 4 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；34.2% PEG 400, 0.36M CaCl2, 0.09M HEPES, 1mM glabridin, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 2.00 Å R-free 0.259
4N87 Crystal structure of V30M mutant human transthyretin complexed with glabridin Deposited 2013-10-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M GBJ 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H,8H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；32% PEG 400, 0.4M CaCl2, 0.1M HEPES, 0.5mM Glabridin, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.79 Å R-free 0.253
4PM1 Human transthyretin (TTR) complexed with 16-alpha-bromo-estradiol Deposited 2014-05-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded ESZ (14beta,16alpha,17alpha)-16-bromoestra-1,3,5(10)-triene-3,17-diol × 4 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.2；293 K；Protein: 5 mg/ml TTR dialysed against 0.1 M NaCl, 0.05M Na acetate, pH 5.5. Precipitant:: 70% (30% PEG 4000, 0.2M imidazole malate, pH 6.0) 30% (18% monomethyl PEG 2000, 0.1 M sodium cacodylate, pH 6.5). Cryoprotectant: 40% (25 % diethylene glycol + 12.5 % MPD + 37.5 % 2,3-butanediol + 12.5 % 1,4-dioxane) 50% (12.5% MPEG 5K, 25% MPEG 550) 0.1 M (mixed Na propionate, Na cacodylate, Bis-Tris-propane 50% at pH 4.0 and 50% pH 9.5)
Resolution 1.23 Å R-free 0.211
4PME Human transthyretin (TTR) complexed with ferulic acid and curcumin. Deposited 2014-05-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–146（118 aa） Fragment：UNP residues 29-145
Chain B 29–146（118 aa） Fragment：UNP residues 29-145
Not recorded CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 2 NA SODIUM ION × 2 EDO 1,2-ETHANEDIOL × 2 FER 3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；protein: 5 mg/ml dialysed in 0.1 M NaCl, 0.05 M NaAc, pH 5.5 with 5 milli-M curcumin. precipitant:: 45% MPEG 2,000, 0.1 M sodium cacodylate, pH 7.5. Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol), 50% (25% MPEG 5000, 0.1 M mixed (Na acetate, ADA, Bicine buffer: 40% pH 4.0 / 60% pH 9.0)
Resolution 1.26 Å R-free 0.207
4PME Human transthyretin (TTR) complexed with ferulic acid and curcumin. Deposited 2014-05-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 29–146（118 aa） Fragment：UNP residues 29-145
Chain B 29–146（118 aa） Fragment：UNP residues 29-145
Not recorded CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 1 NA SODIUM ION × 1 EDO 1,2-ETHANEDIOL × 1 FER 3-(4-HYDROXY-3-METHOXYPHENYL)-2-PROPENOIC ACID × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；protein: 5 mg/ml dialysed in 0.1 M NaCl, 0.05 M NaAc, pH 5.5 with 5 milli-M curcumin. precipitant:: 45% MPEG 2,000, 0.1 M sodium cacodylate, pH 7.5. Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol), 50% (25% MPEG 5000, 0.1 M mixed (Na acetate, ADA, Bicine buffer: 40% pH 4.0 / 60% pH 9.0)
Resolution 1.26 Å R-free 0.207
4PMF Human transthyretin (TTR) complexed with curcumin Deposited 2014-05-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–145（117 aa） Fragment：UNP residues 29-146
Chain B 29–145（117 aa） Fragment：UNP residues 29-146
Not recorded CUR (1Z,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one × 4 NA SODIUM ION × 2 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；Precipitant: 40% MPEG 2,000, 1% dioxane, 0.1 M sodium cacodylate, pH 7.5. Cryoprotectant: 40% mixed (25% dioxane, 25% DMSO, 12.5% ethylene glycol, 12.5% 1,2-propanediol, 12.5% glycerol, 12.5% 2,3-butanediol) 50% (25% MPEG 5K, 0.1 M mixed (sodium acetate, ADA, bicine 20% pH 4 and 80% pH 9), 3 milli-M Curcumin for 20 min
Resolution 1.35 Å R-free 0.209
4PVL X-ray structure of human transthyretin (TTR) at room temperature to 1.9A resolution Deposited 2014-03-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, 100UL DROP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution 1.85 Å R-free 0.201
4PVM Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue) Deposited 2014-03-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution not provided
4PVN Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromatic) Deposited 2014-03-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.4；293 K；2.15M SODIUM MALONATE, 23MG/ML PROTEIN, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 293K
Resolution not provided
4PWE Crystal structure of V30M mutant human transthyretin Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；30% PEG400, 0.1M HEPES, 0.4M CaCl2, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.40 Å R-free 0.228
4PWF Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl ester Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PWF 2-phenylethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 4mM ferulic acid phenethyl ester, pH 7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.60 Å R-free 0.232
4PWG Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl ester Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M 0XR ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 12mM caffeic acid ethyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.243
4PWH Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl ester Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PWH 3-methylbut-2-en-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 9mM caffeic acid 1,1-dimethylallyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.219
4PWI Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acid Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M ROA (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 9mM rosmarinic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.49 Å R-free 0.231
4PWJ Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acid Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M 30Z 4-[(2R,3S)-3-[(3,4-DIHYDROXYPHENYL)METHYL]-2-METHYLBUTYL]BENZENE-1,2-DIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 8mM nordihydroguaiaretic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.55 Å R-free 0.219
4PWK Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acid Deposited 2014-03-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PWK 4,4'-[(2R,3R)-2,3-dimethylbutane-1,4-diyl]bis(2-methoxyphenol) × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 6mM dihydroguaiaretic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.59 Å R-free 0.231
4QRF Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl ester Deposited 2014-06-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M QAP 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；10-30% PEG400, 0.1M HEPES, 0.2M CaCl2, 1mM caffeic acid phenethyl ester, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 1.80 Å R-free 0.256
4QXV CRYSTAL STRUCTURE of HUMAN TRANSTHYRETIN IN COMPLEX WITH LUTEOLIN AT 1.1 A RESOLUTION Deposited 2014-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 GOL GLYCEROL × 6 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 5.5；291 K；WT-TTR CONCENTRATION WAS 5 MG/ML IN 10 MM SODIUMPHOSPHATE PH 7.6, 100 MM POTASSIUMCLORIDE. WT-TTR WAS CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH 5 MOLAR EXCESS OF LUTEOLIN IN 3.5% V/V GLYCEROL AND 1.3-1.6 M SODIUM CITRATE AT PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K
Resolution 1.12 Å R-free 0.152
4QYA Crystal structure of human transthyretin variant V30M in complex with luteolin Deposited 2014-07-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Mutation：V30M Mutation：V30M LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；V30M-TTR CONCENTRATION WAS 5 MG/ML IN 10 MM SODIUMPHOSPHATE, PH 7.6, 100 MM POTASSIUMCLORIDE. V30M-TTR WAS CO-CRYSTALLIZED AT ROOM TEMPERATURE WITH 5 MOLAR EXCESS OF LUTEOLIN IN 3.5% V/V GLYCEROL AND 1.3-1.6 M SODIUM CITRATE AT PH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
Resolution 1.70 Å R-free 0.198
4TKW Crystal Structure of Human Transthyretin Leu55Pro Mutant Deposited 2014-05-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.80 Å R-free 0.200
4TL4 Crystal Structure of Human Transthyretin Val30Met Mutant Deposited 2014-05-28 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.75 Å R-free 0.235
4TL5 Crystal Structure of Human Transthyretin Ser85Pro Mutant Deposited 2014-05-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：S85P Mutation：S85P NA SODIUM ION × 2 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.44 Å R-free 0.198
4TLK Crystal Structure of Human Transthyretin Ser85Pro/Glu92Pro Mutant Deposited 2014-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：S85P, E92P Mutation：S85P, E92P NA SODIUM ION × 4 GOL GLYCEROL × 2 PEG DI(HYDROXYETHYL)ETHER × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.44 Å R-free 0.201
4TLS Crystal Structure of Human Transthyretin Glu92Pro Mutant Deposited 2014-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：E92P Mutation：E92P PO4 PHOSPHATE ION × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.35 Å R-free 0.192
4TLT Crystal structure of human transthyretin Deposited 2014-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.70 Å R-free 0.232
4TLU Crystal Structure of Human Transthyretin Ala108Trp Mutant Deposited 2014-05-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：A108W Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A108W Non-standard monomer：Yes (specific site not provided by mmCIF) CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.75 Å R-free 0.213
4TM9 Crystal Structure of Human Transthyretin Thr119Trp Mutant Deposited 2014-05-31 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：T119W Mutation：T119W No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.70 Å R-free 0.184
4TNE Crystal Structure of Human Transthyretin Thr119Tyr Mutant Deposited 2014-06-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：T119Y Mutation：T119Y GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.55 Å R-free 0.201
4TNF Crystal Structure of Human Transthyretin Lys15Trp Mutant Deposited 2014-06-03 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：K15W Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：K15W Non-standard monomer：Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.60 Å R-free 0.213
4TNG Crystal Structure of Human Transthyretin Thr119Met Mutant Deposited 2014-06-04 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa） Fragment：UNP residues 29-147
Chain B 29–147（119 aa） Fragment：UNP residues 29-147
Mutation：T119M Mutation：T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.60 Å R-free 0.200
4TQ8 Dual binding mode for 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid binding to Human transthyretin (TTR) Deposited 2014-06-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 7BD 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid × 4 EDO 1,2-ETHANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；Protein: 5 mg/ml 1 milli-M ligand Precipitant: 60% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) 40% (24% MPEG-5K, 0.1 M sodium acetate, pH 5.5) Drops: 1 micro-L protein-ligand complex 1 micro-L precipitant. Cryoprotectant:: 40% (12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 12.5 % DMSO + 12.5 % 1,4-dioxane), 25% MPEG 5K, 0.1 M sodium propionate, sodium cacodylate, Bis-Tris-propane(65% component A pH 4; 35% B pH 9.5 and 1 milli-M ligand.
Resolution 1.52 Å R-free 0.210
4TQH Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)ethanoic acid Deposited 2014-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded ES8 [(9H-fluoren-9-ylideneamino)oxy]acetic acid × 4 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；protein: 5 mg/ml 0.05 M NaCl, 0.05 M Na acetate, pH 5.5 with 1 milli-M ligand. Precipitant: 60% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 40% (24% MPEG-5K, 0.1M sodium acetate, pH 5.5). Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 12.5% MPEG 5K, 25% MPEG 550, 100 mM (sodium propionate, sodium cacodylate, Bis-Tris-propane(50% component A pH 4; 50% B pH 9.5) and 1 mM ligand.
Resolution 1.51 Å R-free 0.222
4TQI Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid in a dual binding mode Deposited 2014-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6BD (2S)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methylpropanoic acid × 4 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；protein: TTR 10 mg/ml + ligand 0.66 milli-M in 0.1 M NaCl, 0.05 M Na acetate, pH 5.5. Precipitant: 70% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 30% (12% MPEG-5K, 0.1 M sodium acetate, pH 5.5). Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 10% PEG 10K, 0.1 M (mixed sodium propionate, sodium cacodylate, Bis-Tris-propane) (65% component A pH 4; 35% B pH 9.5)
Resolution 1.25 Å R-free 0.208
4TQP Human transthyretin (TTR) complexed with (R)-3-(9H-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide in a dual binding mode Deposited 2014-06-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 48R (2R)-3-[(9H-fluoren-9-ylideneamino)oxy]-2-methyl-N-(methylsulfonyl)propanamide × 4 GOL GLYCEROL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.7；293 K；Protein: 5 mg/ml in 0.05 M NaCl, 0.05 M sodium acetate, pH 5.5. Precipitant: 60% (30% PEG-4K, 0.2 M imidazole malate, pH 6.0) and 40% (MPEG-5K, 0.1 M sodium acetate, pH 5.5). Cryoprotectant: 40% (25 % diethylene glycol, 12.5 % MPD, 37.5 % 2,3-butanediol, 12.5 % 1,4-dioxane), 12.5% MPEG 5K, 25% MPEG 550, 0.1 M (sodium propionate, sodium cacodylate, Bis-Tris-propane: 50% component A pH 4; 50% B pH 9.5) with 1 milli-M ligand.
Resolution 1.58 Å R-free 0.198
4WNJ Crystal structure of Transthyretin-quercetin complex Deposited 2014-10-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded DMS DIMETHYL SULFOXIDE × 4 QUE 3,5,7,3',4'-PENTAHYDROXYFLAVONE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；Protein (5 mg/ml) in 20 mM sodium phosphate at pH 7. The reservoir solution was 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0
Resolution 1.40 Å R-free 0.193
4WNS Crystal structure of Transthyretin complexed with pterostilbene Deposited 2014-10-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SO4 SULFATE ION × 4 DMS DIMETHYL SULFOXIDE × 6 3RL Pterostilbene × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；The protein (5 mg/ml) was in 20 mM sodium phosphate at pH 7. Reservoir solution: 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0
Resolution 1.40 Å R-free 0.186
4WO0 Crystal structure of transthyretin in complex with apigenin Deposited 2014-10-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded AGI 5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；The protein (5 mg/ml) was in 20 mM sodium phosphate at pH 7. The reservoir solution was 2.0 M ammonium sulfate, 0.1 M KCl, 0.05 M sodium phosphate, pH 7.0.
Resolution 1.34 Å R-free 0.206
4Y9B Crystal structure of V30M mutated transthyretin in complex with alpha-mangostin Deposited 2015-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M MKS 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 CL CHLORIDE ION × 4 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1M NaOAc, 0.2 M CaCl2
Resolution 1.40 Å R-free 0.235
4Y9C Crystal structure of V30M mutated transthyretin with bromide in complex with alpha-mangostin Deposited 2015-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M MKS 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 BR BROMIDE ION × 12 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；20% PEG400, 0.092 M MES, 0.1 M KBr
Resolution 1.49 Å R-free 0.240
4Y9E Crystal structure of V30M mutated transthyretin in complex with gamma-mangostin Deposited 2015-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M MKT 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 CL CHLORIDE ION × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1 M NaOAc, 0.2 M CaCl2
Resolution 1.49 Å R-free 0.219
4Y9F Crystal structure of V30M mutated transthyretin with bromide in complex with gamma-mangostin Deposited 2015-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M MKT 1,3,6,7-tetrahydroxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one × 4 BR BROMIDE ION × 16 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.8；293 K；20% PEG400, 0.092 M MES, 0.1 M KBr
Resolution 1.50 Å R-free 0.221
4Y9G Crystal structure of V30M mutated transthyretin in complex with 3-isomangostin Deposited 2015-02-17 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M MKU 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-3,4-dihydro-2H,6H-pyrano[3,2-b]xanthen-6-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；16% PEG400, 0.1 M NaOAc, 0.2 M CaCl2
Resolution 1.89 Å R-free 0.258
4YDM High resolution crystal structure of human transthyretin bound to ligand and conjugates of 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate Deposited 2015-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) 4AJ 2,6-dichloro-4-[5-(3-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor-diffusion sitting drop method. Crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 M sodium citrate, pH 5.5, containing 10% v/v glycerol
Resolution 1.25 Å R-free 0.172
4YDN High resolution crystal structure of human transthyretin bound to ligand and conjugates of 4-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)phenyl fluorosulfate Deposited 2015-02-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) 2WN 4-[5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenyl sulfurofluoridate × 4 4B8 2,6-dichloro-4-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]phenol × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；The wt-TTR was concentrated to 4 mg/ml in 10 mM NaPi, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature with inhibitors using the vapor-diffusion sitting drop method, crystals were grown from 1.395 M sodium citrate, 3.5% v/v glycerol at ph 5.5. The crystals were frozen using a cryo-protectant solution of 1.395 m sodium citrate, ph 5.5, containing 10% v/v glycerol, vapor diffusion, sitting drop, temperature 298.0
Resolution 1.35 Å R-free 0.195
5A6I V122I Transthyretin structure in complex with Tolcalpone Deposited 2015-06-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：RESIDUES 21-147
Mutation：YES TCW Tolcapone × 4 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.86 Å R-free 0.271
5AKS Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O- glucuronide Deposited 2015-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Not recorded SO4 SULFATE ION × 4 R3X Resveratrol-3-O-glucuronide × 4 DMS DIMETHYL SULFOXIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
Resolution 1.25 Å R-free 0.188
5AKT Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide Deposited 2015-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Not recorded SO4 SULFATE ION × 4 R4G Resveratrol-4'-O-glucuronide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
Resolution 1.35 Å R-free 0.195
5AKV Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: genistein-7-O- glucuronide Deposited 2015-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Not recorded G7G Genistein-7-O-glucuronide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
Resolution 1.52 Å R-free 0.200
5AL0 Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O-sulfate Deposited 2015-03-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Not recorded SO4 SULFATE ION × 4 R3S RESVERATROL-3-O-SULFATE × 4 DMS DIMETHYL SULFOXIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
Resolution 1.39 Å R-free 0.209
5AL8 Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: daidzein-7-O- glucuronide Deposited 2015-03-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：UNP RESIDUES 21-147
Not recorded D75 DAIDZEIN-7-O-GLUCURONIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).
Resolution 1.50 Å R-free 0.198
5AYT Crystal structure of transthyretin in complex with L6 Deposited 2015-09-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded L6Y 2-oxidanyl-6-(phenylcarbonyl)benzo[de]isoquinoline-1,3-dione × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；18% polyethylene glycol 400, 0.1 M HEPES-NaOH, 0.2 M CaCl2, 1 mM L6
Resolution 1.40 Å R-free 0.209
5BOJ Crystal Structure of Human Transthyretin in Complex with Gemfibrozil Deposited 2015-05-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded 4TX 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；TTRwt was dialyzed against 10 mM sodium phosphate with 100 mM KCl pH 7.6 and concentrated to 5 mg/ml. The resevoir contained 1.3-1.6 M sodium citrate and 3.5% glycerol at pH 5.5. Drop size 3 plus 3 microliter.
Resolution 1.75 Å R-free 0.212
5CLX X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolution Deposited 2015-07-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：S52P Mutation：S52P GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.1M di-sodium malonate
Resolution 1.28 Å R-free 0.176
5CLY X-ray structure of TTR mutant - S52P at 1.23A resolution Deposited 2015-07-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：residues 21-147
Chain B 21–147（127 aa） Fragment：residues 21-147
Mutation：S52P Mutation：S52P GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.5M di-sodium malonate
Resolution 1.23 Å R-free 0.186
5CLZ X-ray structure of TTR mutant - T119M at 1.22A resolution Deposited 2015-07-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Mutation：T119M Mutation：T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；2.1M di-sodium malonate
Resolution 1.22 Å R-free 0.197
5CM1 X-ray structure of perdeuterated TTR mutant - T119M at 1.22A Deposited 2015-07-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Mutation：T119M Mutation：T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；2.4M di-sodium malonate
Resolution 1.22 Å R-free 0.196
5CN3 X-ray structure of wild-type TTR at 1.30A resolution Deposited 2015-07-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5；298 K；2.15M di-sodium malonate
Resolution 1.30 Å R-free 0.180
5CNH X-ray structure of perdeuterated wild-type TTR at 1.42A resolution Deposited 2015-07-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：UNP residues 21-147
Chain B 21–147（127 aa） Fragment：UNP residues 21-147
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2.4M di-sodium malonate
Resolution 1.42 Å R-free 0.198
5CR1 Crystal structure of TTR/resveratrol/T4 complex Deposited 2015-07-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Not recorded T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 2 STL RESVERATROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；The protein (5 mg/ml), in 20 mM sodium phosphate, pH 7 was incubated with a reservoir solution containing 2.2 M ammonium sulphate, 0.1 M KCl, 0.03 M sodium phosphate, pH 7.0.
Resolution 1.54 Å R-free 0.193
5DEJ Transthyretin natural mutant A19D Deposited 2015-08-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Mutation：A19D Mutation：A19D CA CALCIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5
Resolution 1.37 Å R-free 0.207
5DEJ Transthyretin natural mutant A19D Deposited 2015-08-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 30-145
Chain B 30–145（116 aa） Fragment：UNP residues 30-145
Mutation：A19D Mutation：A19D CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5
Resolution 1.37 Å R-free 0.207
5DWP Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting and cryo-cooling technology Deposited 2015-09-22 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa） Fragment：UNP residues 31-145
Chain B 30–145（116 aa） Fragment：UNP residues 31-145
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M sodium citrate, 1.6 M ammonium sulfate, pH=5.0
Resolution 1.20 Å R-free 0.196
5E23 Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acid Deposited 2015-09-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded L32 {[(2,7-dibromo-9H-fluoren-9-ylidene)amino]oxy}acetic acid × 2 DMS DIMETHYL SULFOXIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 10mg/ml in .1 M NaCl, .050 M Na acetate, pH 5.5. Complex: 3 micro-L TTR + 3 micro-L 0.02% azide + 1 micro-L inhibitor (.001 M) Precipitant: 18% PEG4K, 9% PEG10K, 0.12 M imidazole malate pH 6.0, 0.04 M ammonium acetate, pH 4.5. Cryoprotectant: 10 % diethylene glycol + 5 % MPD + 15 % 2,3-butanediol + 5 % 1,4-dioxane, 12.5% MPEG 5K, 0.1 M mixed ( Na acetate, ADA, Bicine) 60% pH 4 / 40% pH 9)
Resolution 1.41 Å R-free 0.197
5E4A Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid. Deposited 2015-10-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 10–146（137 aa）
Chain B 10–146（137 aa）
Not recorded 5JW {[(2,7-dichloro-9H-fluoren-9-ylidene)amino]oxy}acetic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: TTR at 5 mg/ml + 1.6 milli-M inhibitor. Precipitant: 18% PEG4K, 0.08M imidazole malate, pH 6.0 and 13.5% PEG10K, 0.06M ammonium acetate, pH 4.5 Cryoprotectant: 10% diethylene glycol + 5% MPD + 15% 2,3-butanediol + 5% 1,4-dioxane, 25% MPEG 5K, 0.1 M mixed (Na acetate, ADA, Bicine - 60% at pH 4/40% at pH 10) 1 milli-M inhibitor.
Resolution 1.33 Å R-free 0.192
5E4O Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acid Deposited 2015-10-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–146（117 aa） Fragment：UNP residues 30-146
Chain B 30–146（117 aa） Fragment：UNP residues 30-146
Not recorded L57 ({(Z)-[(3,4-dichlorophenyl)(phenyl)methylidene]amino}oxy)acetic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Protein: 5mg/ml TTR and 1 milli-M inhibitor. Precipitant: 25% PEG4K, 0.2M imidazole malate, pH 6.0. Slow dessication over 18 months, rehydrated over 4 hours. Cryoprotectant: 40% CryoSol SM1, 25% MPEG 5K, 0.1M (Na acetate, ADA, Bicine, 80% pH 4.0/20% pH 9.0)
Resolution 1.50 Å R-free 0.207
5EN3 Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolution Deposited 2015-11-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 7LU 2-[3,4-bis(oxidanyl)phenyl]-7-chloranyl-5-oxidanyl-chromen-4-one × 4 NA SODIUM ION × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；Purified TTR was dialyzed against 10 mM Naphosphate buffer with 100 mM KCl, pH 7.6 and concentrated to 5 mg per ml. Crystallization solution contained 1.3 to 1.6 M sodium citrate and 3.5% glycerol.
Resolution 1.25 Å R-free 0.158
5EZP Human transthyretin (TTR) complexed with 4-hydroxy-chalcone Deposited 2015-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 26–147（122 aa）
Chain B 26–147（122 aa）
Chain C 26–147（122 aa）
Chain D 26–147（122 aa）
Not recorded IPJ 4-hydroxy-chalcone × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Protein: 5mg/ML in 0.05 M NaCl, 0.025 M Na acetate, pH 5.5 and 0.001 M 4-hydroxychalcone Reservoir: 30% PEG4K, 0.1M Tris-HCl, pH 8.5 4 boosts (5 M NaCl) Cryoprotectant: CryoSol SM1, 25% PEG 4K, 0.1 M (Na acetate, ADA, Bicine) Buffer 20% acid / 80% basic 0.01 M ligand.
Resolution 2.50 Å R-free 0.245
5EZP Human transthyretin (TTR) complexed with 4-hydroxy-chalcone Deposited 2015-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 26–147（122 aa）
Chain F 26–147（122 aa）
Chain G 26–147（122 aa）
Chain H 26–147（122 aa）
Not recorded IPJ 4-hydroxy-chalcone × 2 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Protein: 5mg/ML in 0.05 M NaCl, 0.025 M Na acetate, pH 5.5 and 0.001 M 4-hydroxychalcone Reservoir: 30% PEG4K, 0.1M Tris-HCl, pH 8.5 4 boosts (5 M NaCl) Cryoprotectant: CryoSol SM1, 25% PEG 4K, 0.1 M (Na acetate, ADA, Bicine) Buffer 20% acid / 80% basic 0.01 M ligand.
Resolution 2.50 Å R-free 0.245
5FO2 Structure of human transthyretin mutant A108I Deposited 2015-11-17 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：RESIDUES 21-147
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；0.1M HEPES PH 7.5, 28% PEG400, 0.2M CACL2
Resolution 1.45 Å R-free 0.215
5FW6 Structure of human transthyretin mutant A108V Deposited 2016-02-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：RESIDUES 21-147
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.30 Å R-free 0.203
5FW6 Structure of human transthyretin mutant A108V Deposited 2016-02-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa） Fragment：RESIDUES 21-147
Chain B 21–147（127 aa） Fragment：RESIDUES 21-147
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.30 Å R-free 0.203
5FW7 Structure of human transthyretin mutant A109V Deposited 2016-02-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.20 Å R-free 0.185
5FW8 Structure of human transthyretin mutant E89K Deposited 2016-02-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.204
5FW8 Structure of human transthyretin mutant E89K Deposited 2016-02-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：YES Mutation：YES No recorded non-water small molecule X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.60 Å R-free 0.204
5H0V Crystal structure of H88A mutated human transthyretin Deposited 2016-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa） Fragment：UNP residues 31-147
Chain B 31–147（117 aa） Fragment：UNP residues 31-147
Chain C 31–147（117 aa） Fragment：UNP residues 31-147
Chain D 31–147（117 aa） Fragment：UNP residues 31-147
Mutation：H88A Mutation：H88A Mutation：H88A Mutation：H88A MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；293 K；16% (+/-)-2-methyl-2,4-pentanediol, 0.2 M MgCl2, 0.1 M sodium acetate
Resolution 1.58 Å R-free 0.209
5H0W Crystal structure of H88F mutated human transthyretin Deposited 2016-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa） Fragment：UNP residues 31-147
Mutation：H88F SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES
Resolution 1.90 Å R-free 0.236
5H0X Crystal structure of H88S mutated human transthyretin Deposited 2016-10-07 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa） Fragment：UNP residues 31-147
Chain B 31–147（117 aa） Fragment：UNP residues 31-147
Mutation：H88S Mutation：H88S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.8；293 K；1.8 M ammonium sulfate, 25% glycerol, 0.1 M sodium acetate
Resolution 1.57 Å R-free 0.253
5H0Y Crystal structure of H88Y mutated human transthyretin Deposited 2016-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa） Fragment：UNP residues 31-147
Mutation：H88Y SO4 SULFATE ION × 4 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES
Resolution 1.80 Å R-free 0.243
5H0Z Crystal structure of P113A mutated human transthyretin Deposited 2016-10-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–147（117 aa） Fragment：UNP residues 31-147
Mutation：P113A SO4 SULFATE ION × 4 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；1.6 M Ammonium sulfate, 0.1 M sodium acetate
Resolution 1.74 Å R-free 0.257
5HJG Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA) Deposited 2016-01-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded XDI 4,4'-propane-2,2-diylbis(2,6-dibromophenol) × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
Resolution 1.40 Å R-free 0.182
5IHH Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolution Deposited 2016-02-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6B5 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-4H-1-chromen-4-one × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. 7MeOLut was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
Resolution 1.35 Å R-free 0.166
5JID Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA) Deposited 2016-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 8PF pentadecafluorooctanoic acid × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOA was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
Resolution 1.20 Å R-free 0.163
5JIM Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS) Deposited 2016-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded P8S heptadecafluoro-1-octanesulfonic acid × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
Resolution 1.26 Å R-free 0.158
5JIQ Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2) Deposited 2016-04-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 27M bis(2,4-dihydroxyphenyl)methanone × 4 NA SODIUM ION × 2 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BP2 was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.
Resolution 1.45 Å R-free 0.168
5K1J Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivative Deposited 2016-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded DMS DIMETHYL SULFOXIDE × 4 EDO 1,2-ETHANEDIOL × 6 ACT ACETATE ION × 6 RE RHENIUM × 4 IMD IMIDAZOLE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0 cryosoak: 40% SM2 (12.5 % ethylene glycol, 12.5 % glycerol, 12.5 % 1,2-propanediol, 25 % DMSO and 37.5% 1,4-dioxane) 50% PEG 8K and 0.2 milli-M of rhenium tris-carbonyl Pyta-C8 derivative.
Resolution 1.69 Å R-free 0.222
5K1N Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivative Deposited 2016-05-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa）
Chain B 30–147（118 aa）
Not recorded EDO 1,2-ETHANEDIOL × 4 PEG DI(HYDROXYETHYL)ETHER × 2 RE RHENIUM × 6 ACT ACETATE ION × 2 DMS DIMETHYL SULFOXIDE × 2 IMD IMIDAZOLE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0 + 3.6% polyethylene glycol monomethyl ether (MPEG5K), 30 mM sodium acetate pH 5.5 cryosoak: 40% SM3 (25 % diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 50% PEG 8K and 0.5 milli-M of rhenium tris-carbonyl Pyta-C12 derivative.
Resolution 1.81 Å R-free 0.224
5L4F Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC) Deposited 2016-05-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6J1 2,6-Dinitro-p-cresol × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. DNPC was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
Resolution 1.48 Å R-free 0.194
5L4I Crystal Structure of Human Transthyretin in Complex with Clonixin Deposited 2016-05-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6J3 2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Clonixin was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
Resolution 1.45 Å R-free 0.179
5L4J Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol S, BPS) Deposited 2016-05-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6JD 4-(4-hydroxyphenyl)sulfonylphenol × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BPS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
Resolution 1.62 Å R-free 0.216
5L4M Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid (Triclopyr) Deposited 2016-05-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded SBK Triclopyr × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；291 K；Purified TTRwt was dialyzed against 10 mM sodium phosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Triclopyr was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter
Resolution 1.58 Å R-free 0.198
5LLL Crystal structure of DACM wild type Transthyretin Deposited 2016-07-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M CaCl2 0.1 M HEPES sodium pH 7.5 28% v/v PEG 400
Resolution 1.42 Å R-free 0.217
5LLV Crystal structure of DACM F87M/L110M Transthyretin mutant Deposited 2016-07-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded CL CHLORIDE ION × 3 ACT ACETATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 4.6；293 K；0.2 M CaCl2 0.1 M Sodium Acetate pH 4.6 20% v/v 2-propanol
Resolution 1.70 Å R-free 0.223
5N5Q Human TTR altered conformation from soaking in iron chloride. Deposited 2017-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded ACT ACETATE ION × 6 FFE [bis(oxidanyl)-[tetrakis(oxidanyl)ferriooxy]ferrio]oxy-pentakis(oxidanyl)iron × 2 FE FE (III) ION × 10 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 27 % polyethylene glycol 4,000, 0.2 M imidazole malate, pH 6.0. cryosoak: 40% SM3 (, 25 % MPEG 5K, 25 % diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 25 % MPEG 5K, 0.1 M CHC (citric acid, HEPES, CHES: 90 % acid /10 % basic), 30 mM FeCl2, 2 h soak.
Resolution 2.53 Å R-free 0.253
5N62 Human TTR crystals soaked in manganese chloride. Deposited 2017-02-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–146（117 aa）
Chain B 30–146（117 aa）
Not recorded MN MANGANESE (II) ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 26% polyethylene glycol 4,000 (PEG4K), 0.16 M imidazole malate, pH 6.0 cryosoak: 40 % CM7 (12.5 % di-ethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % DMSO), 25 % MPEG 5K, 5 mM MnCl2, 10 min soak.
Resolution 1.80 Å R-free 0.244
5N7C Human TTR altered conformation from soaking in CuCl2. Deposited 2017-02-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–147（118 aa）
Chain B 30–147（118 aa）
Not recorded CU COPPER (II) ION × 6 PEG DI(HYDROXYETHYL)ETHER × 2 ACT ACETATE ION × 2 EDO 1,2-ETHANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 Precipitant: 21 % PEG4K, .14 M imidazole malate, pH 6.0, 3.6% MPEG 5K, 0.03 M sodium acetate, pH 5.5 cryosoak: 40% CM1 (12.5 % di-ethylene glycol + 12.5 % MPD + 37.5 % 1,2-propanediol + 12.5 % DMSO ), 25 % MPEG 5K,0.1 M CHC (citric acid, HEPES, CHES) 90 % acid at pH 4.0 / 10 % basic at pH 10.0), 30 min soak.
Resolution 2.45 Å R-free 0.254
5NFE Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution Deposited 2017-03-14 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；291 K；1.9M sodium malonate pD5.9, 40mg/ml protein
Resolution not provided
5NFW Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (quasi-Laue) Deposited 2017-03-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded No recorded non-water small molecule Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；1.9M sodium malonate pD 6.4, 25mg/ml protein
Resolution not provided
5OQ0 Crystal structure of transthyretin mutant 87-110-117 Deposited 2017-08-10 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Mutation：F87M/L110M/S117E No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M sodium phosphate (pH 7.5), 2.2 M ammonium sulphate
Resolution 1.94 Å R-free 0.267
5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.70 Å
5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Mutation：L55P Mutation：L55P Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.70 Å
5TTR LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE Deposited 1998-04-30 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Mutation：L55P Mutation：L55P No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions pH 7.5；pH 7.5
Resolution 2.70 Å
5TZL Structure of transthyretin in complex with the kinetic stabilizer 201 Deposited 2016-11-21 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) IIH 4-(7-chloro-1,3-benzoxazol-2-yl)-2,6-diiodophenol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；WT-TTR at 4 mg/mL and five-fold molar excess compound 201 crystallized from solution containing 1.395 M sodium citrate, 3.5% v/v glycerol at pH 5.5. Crystals cryoprotected by addition of 10% (v/v) glycerol.
Resolution 1.40 Å R-free 0.167
5U48 Wild-type Transthyretin in complex with 5-[(1E)-2-(4-Boronic acid)ethenyl]-1,3-benzenediol Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded S4B {4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl}boronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% glycerol
Resolution 1.50 Å R-free 0.205
5U49 Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]-1,3-benzenediol Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Not recorded S2L 5-[(E)-2-(2-chloro-4-hydroxyphenyl)ethenyl]benzene-1,3-diol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 2.22 Å R-free 0.275
5U4A Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]-1,3-benzenediol Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 7VG {3-chloro-4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl}boronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.90 Å R-free 0.276
5U4B Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Hydroxyphenyl)ethenyl]benzoic Acid Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded XOS 3-[(E)-2-(4-hydroxyphenyl)ethenyl]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.45 Å R-free 0.207
5U4C Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Boronic acid)ethenyl]benzoic Acid Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded XBS 3-[(E)-2-(4-boronophenyl)ethenyl]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.70 Å R-free 0.204
5U4D Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]benzoic Acid Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded XLO 3-[(E)-2-(2-chloro-4-hydroxyphenyl)ethenyl]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.55 Å R-free 0.243
5U4E Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]benzoic Acid Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded XLB 3-[(E)-2-(4-borono-2-chlorophenyl)ethenyl]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.45 Å R-free 0.198
5U4F Wild-type Transthyretin in complex with 1,1'-(1E)-(1,2-Ethenediyl)bis[2-chloro-4-boronic acid]benzene Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded IWW [(E)-ethene-1,2-diylbis(3-chloro-4,1-phenylene)]diboronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.50 Å R-free 0.220
5U4G Wild-type Transthyretin in complex with 2-Boronic Acid-1-[(1E)-2-(3-boronic acid)ethenyl]-4-chlorobenzene Deposited 2016-12-03 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 7UV (3-{(E)-2-[2-chloro-4-(hydroxyboranyl)phenyl]ethenyl}phenyl)boronic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M Sodium Citrate, 3.0% Glycerol
Resolution 1.80 Å R-free 0.223
6D0W Structure of human transthyretin complex with analgesic inhibitor Deposited 2018-04-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded FQ7 2-[(3,5-dichlorophenyl)amino]benzoic acid × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M MES, pH 5.5, PEG 4K, 150 mM AmSO4
Resolution 1.70 Å R-free 0.261
6E6Z Structure of Wild Type Human Transthyretin in Complex with Tafamidis Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Not recorded 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.75 Å R-free 0.223
6E70 Structure of Wild Type Human Transthyretin in Complex with Diflunisal Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Not recorded 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.99 Å R-free 0.229
6E71 Structure of Human Transthyretin Val30Met/Thr119Met Mutant Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M,T119M Mutation：V30M,T119M PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；0.2M Lithium Sulfate, 0.1M Tris, 30% (w/v) PEG 4000
Resolution 1.50 Å R-free 0.212
6E72 Structure of Human Transthyretin Val30Met Mutant in Complex with Tafamidis Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：V30M Non-standard monomer：Yes (specific site not provided by mmCIF) 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6；298 K；0.2M Lithium Sulfate Monohydrate, 20% (w/v) PEG 3350
Resolution 1.45 Å R-free 0.205
6E73 Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisal Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M Mutation：V30M 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；20% (W/V) PEG-1000, 0.1M Imidazole, 0.2M Calcium Acetate
Resolution 1.80 Å R-free 0.220
6E74 Structure of Human Transthyretin Leu55Pro Mutant in Complex with Tafamidis Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：L55P Mutation：L55P 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；298 K；0.05 M calcium chloride dihydrate, 0.1 M Bis-Tris, 30% PEG monomethyl ether 550
Resolution 1.60 Å R-free 0.209
6E75 Structure of Human Transthyretin Asp38Ala Mutant Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：D38A Mutation：D38A ACT ACETATE ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；30% (v/v) PEG 400, 100 mM Sodium acetate, 200 mM Calcium acetate
Resolution 1.50 Å R-free 0.207
6E76 Structure of Human Transthyretin Asp38Ala/Thr119Met Mutant Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：D38A, T119M Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：D38A, T119M Non-standard monomer：Yes (specific site not provided by mmCIF) GOL GLYCEROL × 4 SO4 SULFATE ION × 2 ACT ACETATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；50% (w/v) PEG-400, 0.2M Lithium Sulfate, 0.1M Sodium Acetate
Resolution 1.60 Å R-free 0.216
6E77 Structure of Human Transthyretin Asp38Ala Mutant in Complex with Tafamidis Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：D38A Mutation：D38A 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.6；298 K；2.0M Ammonium sulfate, 0.1M Sodium citrate, 0.2M Potassium sodium tartrate tetrahydrate
Resolution 1.60 Å R-free 0.202
6E78 Structure of Human Transthyretin Asp38Ala Mutant in Complex with Diflunisal Deposited 2018-07-25 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：D38A Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：D38A Non-standard monomer：Yes (specific site not provided by mmCIF) 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；298 K；30% (W/V) PEG-400, 0.1M Sodium Acetate, 0.2M Calcium Acetate
Resolution 1.50 Å R-free 0.213
6EOY Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylaniline Deposited 2017-10-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Not recorded BM8 4-(1,3-benzothiazol-2-yl)-2-methyl-aniline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；293 K；acetate buffer 0.2 M pH 4.8-5.4, ammonium sulfate 1.8-2.2 M, 7% glycerol
Resolution 1.38 Å R-free 0.195
6EP1 Transthyretin in complex with 5-(4-nitrophenylazo)-3-iodosalicylic acid Deposited 2017-10-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa） Fragment：UNP Residues 30-144
Chain B 30–144（115 aa） Fragment：UNP Residues 30-144
Not recorded BQB 5-(4-nitrophenylazo)-3-iodosalicylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions EVAPORATION；293 K；acetate buffer 0.2 M pH 4.8-5.4, ammonium sulfate 1.8-2.2 M, 7% glycerol
Resolution 1.30 Å R-free 0.190
6FFT Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temperature to 2A resolution (quasi-Laue) Deposited 2018-01-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：P52S Mutation：P52S 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 4 Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；2.3M sodium malonate pD 5.9
Resolution not provided
6FWD Crystal structure of human transthyretin double mutant R34G/T119M at pH 5.5 Deposited 2018-03-06 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：R34G, T119M Mutation：R34G, T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5
Resolution 1.58 Å R-free 0.229
6FXU Crystal structure of human transthyretin mutant T119M at pH 5.5 Deposited 2018-03-09 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：T119M Mutation：T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5.
Resolution 1.36 Å R-free 0.216
6FZL Crystal structure of human transthyretin double mutant K35T/T119M Deposited 2018-03-15 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：K35T, T119M Mutation：K35T, T119M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；7% glycerol, 1.3 M sodium citrate, pH 5.5
Resolution 1.45 Å R-free 0.192
6GR7 Crystal Structure Of Human Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) Deposited 2018-06-09 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded F52 2-[2,4,5-tris(chloranyl)phenoxy]ethanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；The purified human TTR was dialyzed against 10 mM Na-phosphate buffer with 100 mM KCl (pH 7.6) and concentrated to 5 mg/mL The reservoir contained 28% PEG 4K, 0.1M NaAc pH 4.5, 0.2M AmAc. Drop size 3 plus 3 microliter.
Resolution 1.40 Å R-free 0.188
6GRP Crystal Structure Of Human Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P) Deposited 2018-06-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded F4Z 3,5,6-trichloro-2-pyridinol × 8 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. TC2P was added at 5 x molar excess to the protein. The 1.65 M NaCitrate pH 5.5, 5.8-8.6 % glycerol.
Resolution 1.60 Å R-free 0.187
6IMX Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6 Deposited 2018-10-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG400, 0.1 M MES pH 6.5, 0.4 M CaCl2
Resolution 1.60 Å R-free 0.224
6IMY Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6 Deposited 2018-10-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M AJU 2,3,5,6,8,9,11,12,14,15-decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecine-18-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；27% PEG400, 0.1 M MES pH 6.5, 0.4 M CaCl2
Resolution 1.50 Å R-free 0.209
6KGB Crystal structure of E61K mutated transthyretin Deposited 2019-07-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–146（146 aa）
Chain B 1–146（146 aa）
Mutation：E61K Mutation：E61K CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；27% PEG400, 0.2 M CaCl2, 0.1 M MES-NaOH pH 6.5
Resolution 1.30 Å R-free 0.177
6R66 Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue Deposited 2019-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded JTN 1-[4-[3,5-bis(chloranyl)phenyl]-3-fluoranyl-phenyl]cyclopropane-1-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.30 Å R-free 0.192
6R67 Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue Deposited 2019-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded JTE (2~{R})-2-[4-(3,5-dimethylphenyl)-3-fluoranyl-phenyl]propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.30 Å R-free 0.205
6R68 Crystal structure of transthyretin in complex with CHF4795, a flurbiprofen analogue Deposited 2019-03-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded JTK (2~{R})-2-[4-[3,5-bis(chloranyl)phenyl]-3-fluoranyl-phenyl]propanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.45 Å R-free 0.198
6R6I Crystal structure of transthyretin mutant A25T in complex with CHF5074, a flurbiprofen analogue Deposited 2019-03-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded H50 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid × 4 PO4 PHOSPHATE ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.47 Å R-free 0.218
6SDZ transthyritin derived amyloid fibril from patient with hereditary V30M ATTR amyloidosis Deposited 2019-07-29 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 11 PDB declaration: undecameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Chain I 21–147（127 aa）
Chain J 21–147（127 aa）
Chain K 21–147（127 aa）
Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M Mutation：V30M No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Water extract
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.97 Å
6SUG Crystal structure of transthyretin in complex with 3-deoxytolcapone, a tolcapone analogue Deposited 2019-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded LVB 3-deoxytolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.21 Å R-free 0.170
6SUH Crystal structure of human transthyretin in complex with 3-O-methyltolcapone, a tolcapone analogue Deposited 2019-09-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded LVE 3-O-methyltolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；2.2 M ammonium sulfate, 0.1M KCl, 30 mM sodium phosphate, pH 7.0
Resolution 1.26 Å R-free 0.179
6TI9 Human transthyretin (TTR) complexed with (E)-3-(((3,5-dibromo-2-hydroxybenzylidene)amino)oxy)propanoic acid. Deposited 2019-11-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded ND5 3-[(~{E})-[3,5-bis(bromanyl)-2-oxidanyl-phenyl]methylideneamino]oxypropanoic acid × 4 GOL GLYCEROL × 2 PGO S-1,2-PROPANEDIOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5.
Resolution 1.45 Å R-free 0.182
6TJN Human transthyretin (TTR) complexed with (E)-3-(((4-hydroxybenzylidene)amino)oxy)propanoic acid Deposited 2019-11-26 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded NEK 3-[(~{E})-(4-hydroxyphenyl)methylideneamino]oxypropanoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Reservoir: 24% PEG 600, 0.2 Imidazole Malate pH 5.5.
Resolution 1.70 Å R-free 0.193
6TXV A25T Transthyretin structure in complex with Tolcalpone Deposited 2020-01-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Mutation：A25T Mutation：A25T TCW Tolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.2M CaCl2, 25% PEG400, 0.1M HEPES pH 7.5
Resolution 1.60 Å R-free 0.215
6TXW V30G Transthyretin structure in complex with Tolcalpone Deposited 2020-01-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded TCW Tolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.2M CaCl2, 30% PEG400, 0.1M HEPES pH 7.0
Resolution 1.15 Å R-free 0.185
6U0Q Transthyretin in complex with (E)-5,5'-(ethene-1,2-diyl)bis(1,1-dihydroxy-3-oxo-1,3-dihydrobenzo[c][1,2]oxaborol-1-uide) Deposited 2019-08-14 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded S2B 3-[(~{E})-2-[7,7-bis(oxidanyl)-9-oxidanylidene-8-oxa-7-boranuidabicyclo[4.3.0]nona-1,3,5-trien-3-yl]ethenyl]-7,7-bis(oxidanyl)-8-oxa-7-boranuidabicyclo[4.3.0]nona-1(6),2,4-trien-9-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；1.3 M sodium citrate, 2% v/v glycerol
Resolution 1.75 Å R-free 0.222
6XTK Y114C Transthyretin structure in complex with Tolcalpone Deposited 2020-01-16 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Mutation：Y114C Mutation：Y114C TCW Tolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；0.2M CaCl2, 30% PEG400, 0.1M HEPES, pH 7.0
Resolution 1.70 Å R-free 0.220
7ACU Crystal structure of human transthyretin in complex with Benzbromarone Deposited 2020-09-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Not recorded R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 4.8；293 K；0.2 M acetate buffer pH 4.8, 2.2 M ammonium sulfate, 7% glycerol
Resolution 1.54 Å R-free 0.214
7DT3 Crystal structure of human transthyretin in complex with 4-chloro-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid Deposited 2021-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded CA CALCIUM ION × 4 HG6 4-chloranyl-9,10-bis(oxidanylidene)anthracene-2-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION；293 K；PEG400, CaCl2, sodium acetate
Resolution 1.20 Å R-free 0.186
7DT5 Crystal structure of human transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid Deposited 2021-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded CA CALCIUM ION × 4 HH9 4-chloranyl-9-oxidanylidene-xanthene-2-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.25 Å R-free 0.185
7DT6 Crystal structure of V30M mutated transthyretin in complex with purpurin Deposited 2021-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded 9TF Purpurin × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaC2l, NaOAc
Resolution 1.30 Å R-free 0.211
7DT8 Crystal structure of V30M mutated transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic acid Deposited 2021-01-04 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded CA CALCIUM ION × 4 HH9 4-chloranyl-9-oxidanylidene-xanthene-2-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.25 Å R-free 0.177
7EJQ Crystal structure of human transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid Deposited 2021-04-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–146（146 aa）
Chain B 1–146（146 aa）
Not recorded CA CALCIUM ION × 2 J5R 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.15 Å R-free 0.167
7EJR Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic acid Deposited 2021-04-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–146（146 aa）
Chain B 1–146（146 aa）
Not recorded CA CALCIUM ION × 2 J5R 8-chloranyl-9-oxidanylidene-xanthene-3-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.45 Å R-free 0.207
7ERH Crystal structure of WT-TTR in complex with bithionol Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded B1T 2,2'-sulfanediylbis(4,6-dichlorophenol) × 2 CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, Tris-HCl pH 8, bithionol
Resolution 1.55 Å R-free 0.218
7ERI Crystal structure of V30M-TTR in complex with triclabendazole Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V50M Mutation：V50M JA9 6-[2,3-bis(chloranyl)phenoxy]-5-chloranyl-2-methylsulfanyl-1H-benzimidazole × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.81 Å R-free 0.222
7ERJ Crystal structure of V30M-TTR in complex with dichlorophen Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V50M Mutation：V50M JAL 4-chloranyl-2-[(5-chloranyl-2-oxidanyl-phenyl)methyl]phenol × 4 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc, dichlorophen
Resolution 1.89 Å R-free 0.211
7ERK Crystal structure of V30M-TTR in complex with dasatinib Deposited 2021-05-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V50M Mutation：V50M 1N1 N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, CaCl2, NaOAc
Resolution 1.70 Å R-free 0.222
7OB4 Cryo-EM structure of a twisted-dimer transthyretin amyloid fibril from vitreous body of the eye Deposited 2021-04-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 14 PDB declaration: tetradecameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Chain I 21–147（127 aa）
Chain J 21–147（127 aa）
Chain K 21–147（127 aa）
Chain L 21–147（127 aa）
Chain M 21–147（127 aa）
Chain N 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.22 Å
7Q3I Human Transthyretin expressed in Vibrio natriegens Deposited 2021-10-27 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain AAA 21–147（127 aa）
Chain BBB 21–147（127 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.4；291.15 K；11.6 mg/mL protein in PBS pH 7.4 mixed 1:1 with MgFormate 0.1 M, 24 % PEG1000.
Resolution 1.55 Å R-free 0.227
7Q9L Transthyretin complexed with (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol Deposited 2021-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa）
Chain B 29–147（119 aa）
Not recorded 9RJ 4-[(~{E})-2-naphthalen-1-ylethenyl]benzene-1,2-diol × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；TTR:SB11 complex at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with 1.3-1.6M sodium citrate and 3.5% glycerol.
Resolution 1.45 Å R-free 0.163
7Q9N Transthyretin complexed with (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol Deposited 2021-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa）
Chain B 29–147（119 aa）
Not recorded 9PS 4-[(~{E})-2-naphthalen-2-ylethenyl]benzene-1,2-diol × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；TTR:SB14 complex at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with 1.3-1.6M sodium citrate and 3.5% glycerol.
Resolution 1.45 Å R-free 0.171
7Q9O Complex of Transthyretin with resveratrol exhibits multiple binding modes Deposited 2021-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa）
Chain B 29–147（119 aa）
Not recorded STL RESVERATROL × 4 GOL GLYCEROL × 2 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；protein at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with 1.3-1.6M sodium citrate and 3.5% glycerol.
Resolution 1.35 Å R-free 0.175
7QC5 Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2021-11-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；PEG 400, hepes, calcium chloride
Resolution 1.20 Å R-free 0.175
7THA Crystal structure of human transthyretin variant C10A/M13V Deposited 2022-01-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：C10A, M13V Mutation：C10A, M13V CA CALCIUM ION × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；Crystals of TTR C10A/M13V were grown at 23 degrees C using sitting-drop vapor diffusion by mixing 0.2 microliters of 5 mg/mL protein in 50 mM Tris pH 7.8 and 0.2 microliters of a crystallization buffer consisting of 0.19M CaCl2, 5% (v/v) glycerol, 0.095M HEPES pH 7.5, and 26.6% (v/v) PEG 400. Crystals were frozen directly without additional cryo-protection by plunging in liquid nitrogen
Resolution 1.75 Å R-free 0.211
7W9Q Crystal structure of V30M-TTR in complex with naringenin derivative-14 Deposited 2021-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded 90Q (2~{R})-2-(3-chloranyl-4-oxidanyl-phenyl)-5,7-bis(oxidanyl)-2,3-dihydrochromen-4-one × 4 CA CALCIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, NaOAc, CaCl2
Resolution 1.60 Å R-free 0.201
7W9R Crystal structure of V30M-TTR in complex with naringenin derivative-18 Deposited 2021-12-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded 91C (2~{R})-2-[3,5-bis(chloranyl)-4-oxidanyl-phenyl]-5,7-bis(oxidanyl)-2,3-dihydrochromen-4-one × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG400, NaOAc, CaCl2
Resolution 2.00 Å R-free 0.225
7WL6 Crystal structure of I73L mutated human transthyretin Deposited 2022-01-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I73L Mutation：I73L MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.2；293 K；24% PEG400, 0.2 M magnesium acetate, 5% glycerol, 0.1 M Tris-HCl
Resolution 1.42 Å R-free 0.210
7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain E 1–147（147 aa）
Chain F 1–147（147 aa）
Chain I 1–147（147 aa）
Chain J 1–147（147 aa）
Chain K 1–147（147 aa）
Chain L 1–147（147 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
Resolution 2.79 Å R-free 0.314
7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain G 1–147（147 aa）
Chain H 1–147（147 aa）
Chain M 1–147（147 aa）
Chain N 1–147（147 aa）
Chain O 1–147（147 aa）
Chain P 1–147（147 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
Resolution 2.79 Å R-free 0.314
7Y1I Crystal Structure of TTR-G67R Deposited 2022-06-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 3 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric
Chain Q 1–147（147 aa）
Chain R 1–147（147 aa）
Chain S 1–147（147 aa）
Chain T 1–147（147 aa）
Chain U 1–147（147 aa）
Chain V 1–147（147 aa）
Chain W 1–147（147 aa）
Chain X 1–147（147 aa）
Not recorded No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；AMMONIUM SULFATE, PEG3350
Resolution 2.79 Å R-free 0.314
7Y6J Crystal structure of human transthyretin variant A97S at pH 5.4 Deposited 2022-06-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A97S Mutation：A97S GOL GLYCEROL × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.4；277 K；1.75 M Ammonium sulfate, 0.01 M Citrate buffer, pH 5.4
Resolution 1.38 Å R-free 0.191
7YBR Crystal structure of human transthyretin variant A97S complexed with Tolcapone Deposited 2022-06-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A97S Mutation：A97S TCW Tolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；20% PEG 400, 200 mM Calcium Chloride, 100 mM HEPES
Resolution 1.71 Å R-free 0.219
7YCQ Crystal structure of human transthyretin variant A97S complexed with Diflunisal Deposited 2022-07-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A97S Mutation：A97S 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；277 K；1.5 M Ammonium Sulfate, 0.01M citrate buffer; soaked with 800 micromolar Dilfunisal
Resolution 1.99 Å R-free 0.222
7Z60 Human transthyretin (TTR) complexed with Quercetin 3-O-beta-D-galactoside Deposited 2022-03-10 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 J6O 2-[3,4-bis(oxidanyl)phenyl]-3-[(2S,3R,4S,5R,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one × 2 IMD IMIDAZOLE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 5 mg/ml TTR dialysed against 0.1 M NaCl, 0.05M Na acetate, pH 5.5. Precipitant:80% (30% PEG 4000, 0.2 M Imidazole Malate pH 6.0), 15% ((12% MPEG 5000, 0.1 Sodium Acetate pH 5.5)
Resolution 1.40 Å R-free 0.220
8ADE Wild type ATTR amyloid fibril from senile systemic amyloidosis Deposited 2022-07-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 7 PDB declaration: heptameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.78 Å
8AWI Crystal structure of Human Transthyretin at 1.15 Angstrom resolution Deposited 2022-08-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 29–147（119 aa）
Chain B 29–147（119 aa）
Not recorded NA SODIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；protein at 5.2mg/ml in 10mM sodium phosphate pH7.6 and 100mM potassium chloride was mixed 1:1 with 1.3-1.6M sodium citrate and 3.5% glycerol
Resolution 1.15 Å R-free 0.166
8AWW Transthyretin conjugated with a tafamidis derivative Deposited 2022-08-30 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–145（116 aa）
Chain B 30–145（116 aa）
Not recorded OIT ~{N}-(6-azanylhexyl)-2-[3,5-bis(chloranyl)phenyl]-1,3-benzoxazole-6-carboxamide × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；1.4 M sodium citrate
Resolution 1.60 Å R-free 0.203
8C85 Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 1 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded U1F (3,5-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 M calcium acetate hydrate, 0.1 M Tris 7.5, and 25% w/v PEG 2000 MME
Resolution 1.19 Å R-free 0.168
8C86 Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 2 Deposited 2023-01-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded TQ0 (2,4-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.2 M calcium acetate hydrate, 0.1 M Tris 7.5, and 25% w/v PEG 2000 MME
Resolution 1.10 Å R-free 0.158
8DW5 Complex of Human Transthyretin with 3',5'-Dichlorophenylanthranilic Acid Deposited 2022-07-31 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Not recorded FQ7 2-[(3,5-dichlorophenyl)amino]benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.71；298 K；1.3 M sodium citrate pH 5.71, 3% glycerol
Resolution 1.52 Å R-free 0.235
8E7D Cryo-EM structure of wild-type transthyretin amyloid from heart tissue Deposited 2022-08-23 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.31 Å
8E7E Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient Deposited 2022-08-23 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.61 Å
8E7H Cryo-EM structure of cardiac amyloid fibril from a wild-type amyloidosis patient Deposited 2022-08-23 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.70 Å
8E7I Cryo-EM structure of cardiac amyloid fibril from a variant ATTR P24S amyloidosis patient Deposited 2022-08-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Mutation：P24S Mutation：P24S Mutation：P24S Mutation：P24S Mutation：P24S No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.65 Å
8E7J Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient Deposited 2022-08-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
8G9R Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient Deposited 2023-02-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；H2O, 5 mM EDTA
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.28 Å
8GBR Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient Deposited 2023-02-28 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；fibrils are in water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
8HEJ Crystal structure of Transthyretin in complex with a covalent inhibitor trans-styrylpyrazole Deposited 2022-11-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 31–144（114 aa）
Chain B 31–144（114 aa）
Not recorded XHF 2,6-dibromo-4-[(E)-2-(3,5-dimethyl-1H-pyrazol-4-yl)ethenyl]phenol × 4 XHB 2,4,6-trifluorobenzaldehyde × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；292 K；Sodium Citrate pH5.5, Glycerol
Resolution 1.54 Å R-free 0.223
8HY4 Crystal structure of human transthyretin variant A97S at pH 7.6 Deposited 2023-01-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A97S Mutation：A97S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.6；278 K；0.1 M HEPES, pH 7.6, 38% PEG 400, and 0.4 M CaCl2
Resolution 1.53 Å R-free 0.257
8I00 Crystal structure of A97S transthyretin Deposited 2023-01-10 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A97S Mutation：A97S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；1.6 M Sodium citrate tribasic dihydrate
Resolution 1.80 Å R-free 0.209
8I0O Crystal structure of Transthyretin variant A97S in monomeric form Deposited 2023-01-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S Mutation：F87M, L110M, A97S MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1 M Sodium HEPES; MOPS (acid), 0.3M Sodium fluoride; 0.3M Sodium bromide; 0.3M Sodium iodide, 25% v/v MPD; 25% PEG 1000; 25% w/v PEG 3350
Resolution 1.88 Å R-free 0.234
8IG1 Crystal structure of wild-type transthyretin in complex with rafoxanide Deposited 2023-02-20 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded OX9 ~{N}-[3-chloranyl-4-(4-chloranylphenoxy)phenyl]-3,5-bis(iodanyl)-2-oxidanyl-benzamide × 4 NA SODIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, sodium acetate pH 4.6
Resolution 1.45 Å R-free 0.193
8II1 Crystal structure of V30M-TTR in complex with BID Deposited 2023-02-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PJO Benziodarone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
Resolution 1.91 Å R-free 0.231
8II2 Crystal structure of V30M-TTR in complex with BBM Deposited 2023-02-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 2 CA CALCIUM ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
Resolution 1.80 Å R-free 0.236
8II3 Crystal structure of V30M-TTR in complex with 6-hydroxy BID Deposited 2023-02-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PKK [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
Resolution 1.40 Å R-free 0.212
8II4 Crystal structure of V30M-TTR in complex with 6-hydroxy BBM Deposited 2023-02-24 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PKQ [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, CaCl2, Sodium acetate
Resolution 1.50 Å R-free 0.199
8JNU Crystal structure of V30G mutated human transthyretin Deposited 2023-06-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30G Mutation：V30G MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.8；293 K；PEG400, MgCl2, glycerol
Resolution 1.64 Å R-free 0.207
8JOK Crystal structure of V30L mutated human transthyretin Deposited 2023-06-07 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30L Mutation：V30L MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.9；293 K；PEG400, MgCl2, glycerol
Resolution 1.64 Å R-free 0.215
8JQW Crystal structure of V30I mutated human transthyretin Deposited 2023-06-15 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30I Mutation：V30I MG MAGNESIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；PEG400, MgCl2, glycerol
Resolution 1.80 Å R-free 0.222
8PKE ATTRV20I amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I Mutation：V20I No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.39 Å
8PKF ATTRG47E amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E Mutation：G47E No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.37 Å
8PKG ATTRV122I amyloid fibril from hereditary ATTR amloidosis Deposited 2023-06-26 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I Mutation：V122I No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.99 Å
8PM8 V30M Transthyretin structure in complex with Tolcalpone Deposited 2023-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30M Mutation：V30M TCW Tolcapone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；291.15 K；0.1M HEPES pH 7.5, 0.2M CaCl2, 25% PEG 400
Resolution 1.57 Å R-free 0.231
8PM9 Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1M HEPES pH8, 0.2M CaCl2, 25% PEG 400
Resolution 1.85 Å R-free 0.219
8PMA Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-28 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V30M Mutation：V30M ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH7.0, 0.2M CaCl2, 20% PEG 400
Resolution 1.20 Å R-free 0.201
8PMO Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved TTR Binder) Deposited 2023-06-29 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：V122I Mutation：V122I ZP2 (3-fluoranyl-5-oxidanyl-phenyl)-(3-methoxy-5-nitro-4-oxidanyl-phenyl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 8；291.15 K；0.1M HEPES pH 8.0, 0.2M CaCl2, 30% PEG 400
Resolution 1.24 Å R-free 0.212
8TDN Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, wild-type morphology Deposited 2023-07-04 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；water containing 5-10 mM EDTA
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
8TDO Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, variant-type morphology Deposited 2023-07-04 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4；water containing 5-10 mM EDTA
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
8U52 Co-crystal structure of human transthyretin conjugated to the stilbene substructure derived from reaction with the fluorogenic covalent kinetic stabilizer A2 Deposited 2023-09-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 1W4 S-(4-fluorophenyl) 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzenecarbothioate × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；The WT-TTR was concentrated to 4 mg/mL in 10 mM sodium phosphate, 100 mM KCl, at pH 7.6 and co-crystallized at room temperature using the vapor diffusion sitting drop method.
Resolution 1.50 Å R-free 0.194
8VE0 Human transthyretin covalently modified with A2-derived stilbene in the compressed conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 6 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 3.10 Å
8VE1 Human transthyretin covalently modified with A2-derived stilbene in the canonical conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded 1WZ 3-(dimethylamino)-5-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]benzoic acid × 2 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 6 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 2.70 Å
8VE2 Unliganded human transthyretin in the canonical conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 3.30 Å
8VE3 Unliganded human transthyretin in the compressed conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 3.30 Å
8VE4 Unliganded human transthyretin in the frayed conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 4 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 3.30 Å
8VE5 (Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the compressed conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 3 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 3.40 Å
8VE6 (Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the frayed conformation Deposited 2023-12-18 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded P2C 2-[(3,5-DICHLORO-4-TRIOXIDANYLPHENYL)AMINO]BENZOIC ACID × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.6
cryo-EM vitrification conditions Cryogen ETHANE；3 uL of sample were applied onto the graphene side of the grid after it was mounted on the plunger (always at the same height), and immediately blotted for 3 seconds by holding a 1 x 6 cm piece of Whatman 1 filter paper parallel to the grid, in full contact. Timing was kept with the help of a metronome. The blotting countdown was started after the blotted liquid spot on the filter paper stopped spreading and the grid was plunged in liquid ethane at the same time the blotting paper was pulled back, in a single motion.
Resolution 4.10 Å
8W1N Structure of transthyretin pathogenic mutation A120S Deposited 2024-02-16 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：A120S Mutation：A120S No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1 M MES at pH 6.0, 10% (v/v) glycerol, 5% (w/v) PEG 1000, and 30% (v/v) PEG 600
Resolution 1.60 Å R-free 0.284
8W2W Structure of transthyretin synthetic mutation A120L Deposited 2024-02-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Mutation：A120L No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1 M sodium cacodylate (pH 6.5), 1M sodium chloride, 10% (v/v) glycerol, and 30% (v/v) PEG 600
Resolution 2.07 Å R-free 0.235
8W42 X-ray crystal structure of V30M-TTR in complex with resveratrol Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M STL RESVERATROL × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.45 Å R-free 0.180
8W43 X-ray crystal structure of V30M-TTR in complex with piceatannol Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M PIT PICEATANNOL × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.30 Å R-free 0.181
8W44 X-ray crystal structure of V30M-TTR in complex with oxyresveratrol Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M EZE trans-oxyresveratrol × 6 NA SODIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.40 Å R-free 0.181
8W45 X-ray crystal structure of V30M-TTR in complex with pinostilbene Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M 8KZ 3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-methoxy-phenol × 4 NA SODIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.10 Å R-free 0.165
8W46 X-ray crystal structure of V30M-TTR in complex with pterostilbene Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M 3RL Pterostilbene × 6 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.35 Å R-free 0.188
8W47 X-ray crystal structure of V30M-TTR in complex with isorhapontigenin Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M P5O 5-[(~{E})-2-(3-methoxy-4-oxidanyl-phenyl)ethenyl]benzene-1,3-diol × 4 NA SODIUM ION × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution 1.40 Å R-free 0.171
8W48 Neutron and X-ray joint structure of WT-TTR in complex with piceatannol Deposited 2023-08-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Not recorded PIT PICEATANNOL × 4 Experimental method not declared
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Disodium malonate, 0.1M NaOAc pH 4.6
Resolution not provided
8WGS Crystal structure of V30M-TTR in complex with compound 4 Deposited 2023-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M WGH [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-4-iodanyl-1-benzofuran-3-yl)methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
Resolution 1.80 Å R-free 0.214
8WGT Crystal structure of V30M-TTR in complex with compound 7 Deposited 2023-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M WGJ [4,7-bis(chloranyl)-2-ethyl-1-benzofuran-3-yl]-[3,5-bis(iodanyl)-4-oxidanyl-phenyl]methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
Resolution 1.70 Å R-free 0.231
8WGU Crystal structure of V30M-TTR in complex with compound 20 Deposited 2023-09-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M WH0 [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-[2-ethyl-4,7-bis(fluoranyl)-1-benzofuran-3-yl]methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；PEG 400, sodium acetate, calcium chloride
Resolution 1.51 Å R-free 0.213
8YQD Crystal structure of human transthyretin variant A97S in complex with Tafamidis Deposited 2024-03-19 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–144（124 aa）
Chain B 21–144（124 aa）
Mutation：A97S Mutation：A97S 3MI 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 6.2；310 K；0.05 M Calcium chloride dihydrate +0.1 M Bis-Tris +25% PEG 550
Resolution 1.69 Å R-free 0.225
8Z9V Amyloid beta and TTR Deposited 2024-04-23 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric
Chain A 21–147（127 aa）
Chain b 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.82
cryo-EM vitrification conditions Cryogen NITROGEN
Resolution 7.84 Å
9BDM Cryo-EM structure of cardiac amyloid fibril from a variant ATTRV122delta, single filament morphology Deposited 2024-04-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；ice-chilled water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.63 Å
9BDR Cryo-EM structure of cardiac amyloid fibril from a variant ATTRV122delta, double filament morphology 1 Deposited 2024-04-12 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 10 PDB declaration: decameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Chain I 21–147（127 aa）
Chain J 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Fibrils were purified in ice-chilled water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.82 Å
9BYN Cryo-EM structure of amyloid fibril extracted from nerve of a variant ATTR V30M amyloidosis patient Deposited 2024-05-23 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Milli-Q water
cryo-EM vitrification conditions Cryogen ETHANE；Blot-force 0, blotting time 3 sec
Resolution 3.36 Å
9BZS Cryo-EM structure of cardiac amyloid fibril from a variant ATTR V30M amyloidosis patient Deposited 2024-05-24 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；Milli-Q water
cryo-EM vitrification conditions Cryogen ETHANE；Blot-force 0, blotting time 3 sec
Resolution 3.14 Å
9D21 Cryo-EM structure of amyloid fibril extracted from heart of a variant ATTR T60A amyloidosis patient 1 Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
9D23 Cryo-EM structure of amyloid fibril extracted from heart of a variant ATTR T60A amyloidosis patient 2 Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.18 Å
9D24 Cryo-EM structure of amyloid fibril extracted from thyroid of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.98 Å
9D27 Cryo-EM structure of amyloid fibril extracted from kidney of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.19 Å
9D2G Cryo-EM structure of amyloid fibril extracted from liver of a variant ATTR T60A amyloidosis patient 3 Deposited 2024-08-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；We used water as the buffer for the final elution of fibrils
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
9FF6 Human transthyretin (TTR) in complex with (E)-4-((((2-methoxybenzyl)oxy)imino)methyl)benzoic acid (Lic157) Deposited 2024-05-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–145（125 aa）
Chain B 21–145（125 aa）
Not recorded A1ICE 4-[(~{Z})-(2-methoxyphenyl)methoxyiminomethyl]benzoic acid × 2 GOL GLYCEROL × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5
Resolution 1.40 Å R-free 0.203
9FF8 Human transthyretin (TTR) in complex with (E)-2-((((2-chlorobenzyl)oxy)imino)methyl)benzoic acid (Lic166) Deposited 2024-05-22 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded EDO 1,2-ETHANEDIOL × 2 A1ICF 2-[(2-chlorophenyl)methoxyiminomethyl]benzoic acid × 2 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5.
Resolution 1.42 Å R-free 0.214
9FHA Human transthyretin (TTR) in complex with (E)-2-((((2-(trifluoromethyl)benzyl)oxy)imino)methyl)benzoic acid Deposited 2024-05-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded A1IC9 2-[(~{E})-[2-(trifluoromethyl)phenyl]methoxyiminomethyl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Protein: 4.93 mg/mL, Tris pH 8.0, 150mM NaCl. Precipitant: 24% PEG 600, 0.2M imidazole malate pH 5.5
Resolution 1.70 Å R-free 0.234
9H5X Crystal structure of human V122I transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2024-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–145（125 aa）
Chain B 21–145（125 aa）
Not recorded AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH 7.0, 0.2M CaCl2, 25% PEG 400
Resolution 1.70 Å R-free 0.222
9H5Y Crystal structure of human V30M transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3-fluoro-5-hydroxyphenyl)methanone compound Deposited 2024-10-23 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–145（125 aa）
Chain B 21–145（125 aa）
Not recorded AQI (3-fluoranyl-5-oxidanyl-phenyl)-[3-nitro-4,5-bis(oxidanyl)phenyl]methanone × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；0.1M HEPES pH 7.0, 0.2M CaCl2, 25% PEG 400
Resolution 1.67 Å R-free 0.220
9H7A Human Transthyretin in Complex with 3,5-Dichlorobenzenesulfonamide Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded 6OT 3,5-dichlorobenzene-1-sulfonamide × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.76 Å R-free 0.226
9H7B Human Transthyretin in Complex with Biphenyl-4-carboxylic Acid Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 Z7Z biphenyl-4-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.51 Å R-free 0.228
9H7C Human Transthyretin in Complex with 4-(1H-imidazol-1-yl)phenol Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 MSR 4-(1H-IMIDAZOL-1-YL)PHENOL × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.27 Å R-free 0.209
9H7D Human Transthyretin in Complex with 2-(phenylamino)benzoic acid Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 EHO 2-phenylazanylbenzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.23 Å R-free 0.188
9H7E Human Transthyretin in Complex with 4-pyridin-3-ylbenzoic acid Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 PQM 4-(pyridin-3-yl)benzoic acid × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.43 Å R-free 0.291
9H7F Human Transthyretin in Complex with 3,5-dichloroaniline Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded A1ISU 3,5-bis(chloranyl)aniline × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.24 Å R-free 0.178
9H7G Human Transthyretin in Complex with 1H-indole-3-carbonitrile Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 98Z 1~{H}-indole-3-carbonitrile × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.49 Å R-free 0.210
9H7H Human Transthyretin in Complex with Isoquinolin-3-amine Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 WLX isoquinolin-3-amine × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.47 Å R-free 0.215
9H7I Human Transthyretin in Complex with 4-(1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 A1ISS 4-(1H-pyrazol-4-yl)quinoline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.21 Å R-free 0.183
9H7J Human Transthyretin in Complex with 5-methyl-4-phenyl-1H-pyrazol-3-amine Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 A1ISY 5-methyl-4-phenyl-1H-pyrazol-3-amine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.30 Å R-free 0.260
9H7K Human Transthyretin in Complex with 8-(3,5-dimethyl-1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 6 A1IS2 8-(3,5-dimethyl-1H-pyrazol-4-yl)quinoline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.60 Å R-free 0.236
9H7L Human Transthyretin in Complex with 4-phenyl-1H-pyrazolo[3,4-b]pyridin-3-amine Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 A1IS0 4-phenyl-2H-pyrazolo[3,4-b]pyridin-3-amine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.18 Å R-free 0.192
9H7M Human Transthyretin in Complex with 4-(quinolin-8-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 A1ISV 4-quinolin-8-yl-1H-pyrazolo[3,4-d]pyrimidin-6-amine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.27 Å R-free 0.191
9H7N Human Transthyretin in Complex with 4-(5-methyl-1H-1,2,4-triazol-3-yl)quinoline Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 A1IST 4-(5-methyl-4H-1,2,4-triazol-3-yl)quinoline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.26 Å R-free 0.205
9H7O Human Transthyretin in Complex with 5-(quinolin-8-yl)pyrimidin-2-amine Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 2 A1ISZ 5-quinolin-8-ylpyrimidin-2-amine × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.24 Å R-free 0.193
9H7P Human Transthyretin S52P Mutant in Complex with 4-(1H-pyrazol-4-yl)quinoline Deposited 2024-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Not recorded CA CALCIUM ION × 4 A1ISS 4-(1H-pyrazol-4-yl)quinoline × 4 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.5；294.15 K；100 mM HEPES, 200 mM CaCl2, 28% v/v PEG400, pH 7.5
Resolution 1.36 Å R-free 0.205
9HX3 Amyloid fibril of TTR Deposited 2025-01-06 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
9HYW Cryo-EM structure of ATTRv-F64S amyloid fibril from patient skin tissue. Deposited 2025-01-10 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Chain F 1–147（147 aa）
Chain G 1–147（147 aa）
Chain H 1–147（147 aa）
Chain I 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.80 Å
9JIQ Crystal structure of V30M-TTR in complex with bromoxynil Deposited 2024-09-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M A1L36 bromoxynil × 8 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
Resolution 1.78 Å R-free 0.249
9JIR Crystal structure of V30M-TTR in complex with ioxynil Deposited 2024-09-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M A1L37 ioxynil × 6 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
Resolution 1.30 Å R-free 0.197
9JIS Crystal structure of V30M-TTR in complex with aclonifen Deposited 2024-09-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Mutation：V30M Mutation：V30M A1L38 Aclonifen × 4 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Disodium malonate, 0.1 M NaOAc pH 4.6
Resolution 1.41 Å R-free 0.189
9NNN Cryo-EM structure of amyloid fibril extracted from the heart of a variant ATTR D38A amyloidosis patient Deposited 2025-03-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；fibrils were eluted in ice-cold water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
9PX6 ATTR cardiac amyloid fibrils apex1 Deposited 2025-08-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Chain F 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.20 Å
9PX7 ATTR cardiac amyloid fibrils apex2 Deposited 2025-08-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Chain F 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
9PX9 ATTR V122I cardiac amyloid fibrils Deposited 2025-08-05 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric
Chain A 1–147（147 aa）
Chain B 1–147（147 aa）
Chain C 1–147（147 aa）
Chain D 1–147（147 aa）
Chain E 1–147（147 aa）
Chain F 1–147（147 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
9RGK Human Transthyretin I107V Mutant Deposited 2025-06-06 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Mutation：I107V Mutation：I107V GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2M (NH4)2SO4; 100 mM citrate buffer pH 5.5; 7 v/v % glycerol
Resolution 1.70 Å R-free 0.217
9RSP Cryogenic crystal structure of the perdeuterated TTR mutant V30M at pH5. Deposited 2025-07-01 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；1.7 M Sodium Malonate pH 5
Resolution 1.61 Å R-free 0.201
9RSR Cryogenic crystal structure of the TTR mutant V30M at pH5. Deposited 2025-07-01 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；2.15 M sodium malonate pH 5
Resolution 1.25 Å R-free 0.209
9RTO Room temperature crystal structure of the perdeuterated TTR mutant V30M at pH5. Deposited 2025-07-03 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 30–144（115 aa）
Chain B 30–144（115 aa）
Mutation：V30M Mutation：V30M No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；1.7 M sodium malonate pH5
Resolution 1.56 Å R-free 0.198
9WPB Crystal structure of human transthyretin (TTR) with pryazole-based stabilizer Deposited 2025-09-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Not recorded A1MB7 4-[2-[3,5-bis(chloranyl)-1~{H}-pyrazol-4-yl]ethyl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2M CaCl2, 20% w/v PEG 3350
Resolution 1.58 Å R-free 0.180
9WPB Crystal structure of human transthyretin (TTR) with pryazole-based stabilizer Deposited 2025-09-08 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain E 21–147（127 aa）
Chain F 21–147（127 aa）
Chain G 21–147（127 aa）
Chain H 21–147（127 aa）
Not recorded A1MB7 4-[2-[3,5-bis(chloranyl)-1~{H}-pyrazol-4-yl]ethyl]benzoic acid × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；291 K；0.2M CaCl2, 20% w/v PEG 3350
Resolution 1.58 Å R-free 0.180
9ZBV Human TTR-C10A at pH 7.4 Deposited 2025-11-21 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Mutation：C10A Mutation：C10A Mutation：C10A Mutation：C10A No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.20 Å
9ZLD Cryo-EM structure of hepatic amyloid fibril from a variant ATTRV122delta, single filament morphology Deposited 2025-12-08 Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric
Chain A 21–147（127 aa）
Chain B 21–147（127 aa）
Chain C 21–147（127 aa）
Chain D 21–147（127 aa）
Chain E 21–147（127 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7；ice-chilled water
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.90 Å

460 other PDB entries and 501 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name TTHY_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 1–11； UniProt 125–135 Author chain B； PDBConstruct 1–11； UniProt 125–135 Author chain C； PDBConstruct 1–11； UniProt 125–135 Author chain D； PDBConstruct 1–11； UniProt 125–135 Author chain E； PDBConstruct 1–11； UniProt 125–135 Author chain F； PDBConstruct 1–11； UniProt 125–135 Author chain G； PDBConstruct 1–11； UniProt 125–135 Author chain H； PDBConstruct 1–11； UniProt 125–135 Author chain I； PDBConstruct 1–11； UniProt 125–135 Author chain J； PDBConstruct 1–11； UniProt 125–135 Author chain K； PDBConstruct 1–11； UniProt 125–135 Author chain L； PDBConstruct 1–11； UniProt 125–135 Author chain M； PDBConstruct 1–11； UniProt 125–135 Author chain N； PDBConstruct 1–11； UniProt 125–135 Author chain O； PDBConstruct 1–11； UniProt 125–135 Author chain P； PDBConstruct 1–11； UniProt 125–135

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 2m5n

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 2m5n
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id2m5n
Deposition date deposition_date2013-02-27
Structure title titleAtomic-resolution structure of a cross-beta protofilament
Keywords keywordsAmyloid fibril, Cross-beta structure, PROTEIN FIBRIL; PROTEIN FIBRIL
Experimental Method methodSOLID-STATE NMR
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier16.62 Å
Radius of gyration Rg (electron density) rg_electron16.40 Å
Forward intensity I(0) i01444330000.00
Molecular weight molecular_weight383480.0 kDa
Excluded volume excluded_volume502360 ų
Envelope volume envelope_volume29837 ų
Hydration-shell volume shell_volume14947 ų
Envelope diameter envelope_diameter57.2 Å
Shell Rg shell_rg22.80 Å
Envelope Rg envelope_rg17.32 Å
Shape Rg shape_rg16.43 Å
Total Rg total_rg16.33 Å
Total atoms total_atoms55040
Residues n_residues3520
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax49.5 Å
Rg (real space) rg_real16.58 Å
Rg uncertainty (real space) rg_real_error0.27 Å
I(0) (real space) i0_real1.4440e+09
I(0) uncertainty (real space) i0_real_error1.7970e+07
Rg (reciprocal space) rg_reciprocal16.59 Å
I(0) (reciprocal space) i0_reciprocal1444000000.0000
Solution quality estimate total_estimate0.9019
Solution quality rating solution_quality EXCELLENT a EXCELLENT solution
P(r) peaks n_peaks3
Primary peak position r_peak_primary14.1 Å
Skewness Skewness skewness0.134
Kurtosis Kurtosis kurtosis-0.721
Angular range angular_range— – 0.4800 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha949000.0000
Real-space data points n_real_points78
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.946; Stabil: 0.998; Sysdev: 1.000; Positv: 1.000; Valcen: 0.982; Smooth: 0.906
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (1)

▶

8. Citations (1)

▶

9. Files and Curves (10)